{"gene":"PIM2","run_date":"2026-06-10T06:43:35","timeline":{"discoveries":[{"year":2003,"finding":"Pim-2 phosphorylates the BH3 pro-apoptotic protein BAD and maintains rapamycin-resistant phosphorylation of the translational repressor 4E-BP1, thereby promoting cell survival independently of the PI3K/Akt/TOR pathway. Pim-2 also maintained cell size and mitochondrial potential.","method":"Constitutive expression in hematopoietic cells, Western blot for phospho-substrates, rapamycin resistance assay, growth factor withdrawal survival assay","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (substrate phosphorylation, pathway independence from PI3K/Akt/TOR, survival assays), replicated across several apoptotic stimuli in same study and confirmed by independent labs","pmids":["12869584"],"is_preprint":false},{"year":2003,"finding":"PIM-2 directly phosphorylates BAD on serine 112, and this phosphorylation accounts in part for its ability to reverse BAD-induced cell death. Three PIM-2 protein isoforms are produced in cytokine-treated cells; all three are active kinases, and the short (34 kDa) form is the most active at enhancing survival.","method":"In vitro kinase assay, overexpression in FDCP1 cells, Western blot, caspase activation assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct in vitro kinase assay identifying substrate and phosphorylation site, replicated functionally in cell-based survival assays, consistent with independent reports on BAD phosphorylation","pmids":["12954615"],"is_preprint":false},{"year":1995,"finding":"Pim-2 is 53% identical to Pim-1 at the amino acid level, shares substrate preference and usage of non-AUG initiation codons with Pim-1, and is X-linked. Proviral activation of Pim-2 compensates for loss of Pim-1 in Eµ-myc/Pim-1−/− mice, indicating functional redundancy and placement in the same oncogenic pathway.","method":"PCR-based gene identification, proviral tagging in compound mutant mice (complementation tagging genetic epistasis), sequence analysis","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis in vivo (complementation tagging), replicated by multiple independent proviral insertions; foundational identification paper","pmids":["7781606"],"is_preprint":false},{"year":2004,"finding":"Pim-2-mediated cell survival is dependent on NF-κB activation. Pim-2 phosphorylates and activates the kinase Cot, leading to augmented IκB kinase activity and a shift in nuclear NF-κB from p50 homodimers to p50/p65 heterodimers. Blockade of NF-κB eliminates Pim-2-mediated survival, and Pim-2-driven oncogenesis in vivo requires sustained NF-κB activity.","method":"Reporter assays for NF-κB activity, co-immunoprecipitation, NF-κB blockade, in vivo lymphoma model, primary cell experiments","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (reporter assay, Co-IP, primary cell rescue, in vivo model), clear epistasis placing Pim-2 upstream of Cot/IKK/NF-κB","pmids":["15548703"],"is_preprint":false},{"year":2013,"finding":"Pim2 directly phosphorylates TSC2 on Ser-1798, relieving TSC2 suppression of mTOR-C1 and thereby promoting MM cell proliferation. TSC2 is identified as a novel Pim2 substrate.","method":"shRNA knockdown, selective small-molecule inhibitor, in vitro kinase assay, co-immunoprecipitation, phospho-specific Western blot","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct in vitro phosphorylation of TSC2, genetic and pharmacological inhibition with consistent phenotype, single lab with multiple orthogonal methods","pmids":["23818547"],"is_preprint":false},{"year":2009,"finding":"Crystal structure of PIM2 kinase in complex with an organoruthenium inhibitor was determined, revealing key differences in the ATP-binding site compared with PIM1 that can be exploited for isoform-selective inhibitor design.","method":"X-ray crystallography","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structure with functional inhibitor bound, single study but high-quality structural method","pmids":["19841674"],"is_preprint":false},{"year":2018,"finding":"PIM2 directly binds to hexokinase-2 (HK2) and phosphorylates HK2 on Thr473, increasing HK2 enzyme activity and glycolysis and stabilizing HK2 protein through the chaperone-mediated autophagy (CMA) pathway. This promotes breast cancer cell growth and paclitaxel resistance.","method":"Co-immunoprecipitation, in vitro kinase assay, site-directed mutagenesis, glycolysis assay, xenograft mouse model","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct in vitro kinase assay with mutagenesis, biochemical pathway analyses (CMA), in vivo validation; single lab with multiple orthogonal methods","pmids":["29985480"],"is_preprint":false},{"year":2015,"finding":"Pim-2 kinase phosphorylates the N-terminal domain of Foxp3 at multiple sites, leading to decreased suppressive function of regulatory T cells (Tregs), altered expression of Treg-related proteins, and increased Treg lineage stability. Pharmacological or genetic inhibition of Pim-2 enhances Treg suppressive function.","method":"In vitro kinase assay, genetic knockout in murine Treg cells, pharmacological inhibition, DSS-induced colitis model","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct in vitro phosphorylation of Foxp3, genetic knockout with defined immunological phenotype, in vivo disease model; single lab with multiple orthogonal methods","pmids":["25987564"],"is_preprint":false},{"year":2019,"finding":"PIM2 directly phosphorylates HSF1 at Thr120, disrupting HSF1 binding to the E3 ubiquitin ligase FBXW7 and stabilizing HSF1 protein. Thr120 phosphorylation promotes HSF1 binding to the PD-L1 promoter and enhances PD-L1 expression, driving breast cancer tumorigenesis.","method":"In vitro kinase assay, co-immunoprecipitation, site-directed mutagenesis, chromatin immunoprecipitation, xenograft model","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct in vitro phosphorylation with mutagenesis, ChIP linking phosphorylated substrate to downstream transcription, in vivo validation; single lab with multiple orthogonal methods","pmids":["31409638"],"is_preprint":false},{"year":2013,"finding":"PIM2 binds to and directly phosphorylates pyruvate kinase M2 (PKM2) on Thr-454, increasing PKM2 protein levels and promoting glycolysis (the Warburg effect). The phosphorylation-defective PKM2 mutant shows reduced glycolysis, co-activation of HIF-1α and β-catenin, and increased mitochondrial respiration.","method":"Multiple biochemical pulldown/co-IP approaches in vitro and in cells, in vitro kinase assay, phosphorylation-defective mutant analysis, glycolysis assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct in vitro phosphorylation with mutant validation, multiple biochemical interaction methods, glycolytic functional readouts; single lab","pmids":["24142698"],"is_preprint":false},{"year":2011,"finding":"RAG-induced DNA double-strand breaks activate ATM, which induces Pim2 kinase expression in pre-B cells. Pim2 then phosphorylates BAD to promote survival, but unlike IL-7-induced Pim1, Pim2 has antiproliferative functions that prevent pre-B cells with RAG DSBs from entering S phase.","method":"Genetic mouse model (ATM deficiency, Pim2 knockout), BAD phosphorylation Western blot, cell cycle analysis, survival assays","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic epistasis with ATM KO and Pim2 KO, clear context-dependent functional distinction from Pim1, multiple readouts; single lab","pmids":["22201128"],"is_preprint":false},{"year":2019,"finding":"PIM2 binds to AMPKα1 and directly phosphorylates it on Thr467, leading to decreased AMPKα1 kinase activity, which in turn promotes aerobic glycolysis and tumor growth in endometrial cancer.","method":"Co-immunoprecipitation, in vitro kinase assay, site-directed mutagenesis, glycolysis assay, xenograft and PIM2 KO mouse models","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct in vitro kinase assay with defined phosphorylation site, KO mouse validation, functional glycolysis and tumor growth readouts; single lab with multiple orthogonal methods","pmids":["31358902"],"is_preprint":false},{"year":2010,"finding":"Pim-2 phosphorylates the cell cycle inhibitor p21(Cip1/WAF1) on Thr145 in vitro and in vivo, enhancing p21 protein stability and resulting in G1/S cell cycle arrest and inhibition of cell proliferation in HCT116 cells. Pim-2 does not influence nuclear localization of p21 in these cells.","method":"In vitro kinase assay, overexpression and siRNA knockdown, Western blot for p21 stability, cell cycle analysis","journal":"The international journal of biochemistry & cell biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct in vitro kinase assay, in vivo phosphorylation confirmed, genetic manipulation with defined cell cycle phenotype; single lab","pmids":["20307683"],"is_preprint":false},{"year":2015,"finding":"The forkhead transcription factor CHES1/FOXN3 directly binds the PIM2 promoter and represses PIM2 expression. Reduced PIM2 leads to decreased phosphorylation of 4E-BP1, and overexpression of PIM2 or eIF4E partially reverses the antiproliferative effect of CHES1, placing PIM2 downstream of CHES1 in a protein biosynthesis control pathway.","method":"Chromatin immunoprecipitation, shRNA knockdown, rescue overexpression, 4E-BP1 phosphorylation Western blot","journal":"Molecular biology of the cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP for direct promoter binding, epistasis via rescue experiment, multiple cell lines; single lab","pmids":["24403608"],"is_preprint":false},{"year":2015,"finding":"PIM2 promotes persistent STAT3 activation through induction of cytokines, and activated STAT3 in turn increases PIM2 expression, forming a positive feedback loop. This loop drives EMT in breast cancer via ZEB1, and targeting either PIM2, STAT3, or PIM2-dependent cytokines suppresses migratory and invasive properties.","method":"Genetic knockdown/overexpression, cytokine neutralization, migration/invasion assays, Western blot","journal":"Cancer science","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — functional genetic experiments with signaling readouts, but mechanistic depth is limited (no direct substrate assay); single lab","pmids":["25854938"],"is_preprint":false},{"year":2013,"finding":"Pim-2 co-expresses with eIF4B in prostate cancer cells and determines the phosphorylation level of eIF4B; higher Pim-2 expression correlates with more eIF4B phosphorylation and lower apoptosis. siRNA knockdown of Pim-2 reduces p-eIF4B and increases apoptosis.","method":"siRNA knockdown, transfection overexpression, Western blot for p-eIF4B, apoptosis assay, immunofluorescence co-localization","journal":"The Prostate","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — correlation-based phosphorylation evidence without direct in vitro kinase assay for eIF4B; multiple cell line experiments; single lab","pmids":["23813671"],"is_preprint":false},{"year":2009,"finding":"Pim-2 activates API-5 phosphorylation via the NF-κB pathway to inhibit apoptosis of liver cells; NF-κB inhibition by parthenolide reverses Pim-2-induced API-5 phosphorylation and increases apoptosis.","method":"Transfection and siRNA, NF-κB activity assay, Western blot for phospho-API-5, apoptosis analysis with NF-κB inhibitor parthenolide","journal":"Pathology oncology research","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — genetic manipulation plus pharmacological inhibition with defined signaling readouts; no direct in vitro kinase assay; single lab","pmids":["19821157"],"is_preprint":false},{"year":2011,"finding":"Pim-2 kinase controls autophagy in chondrocytes: it promotes expression and organization of autophagic proteins LC3 and Beclin-1, enhances lysosomal acidification, and modulates BAD activity. PIM-2-silenced chondrocytes show disrupted autophagic response. These effects are independent of Akt-1.","method":"siRNA silencing, immunofluorescence for LC3/Beclin-1, lysosomal acidification assay, rapamycin sensitization, Akt-1 independence controls","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA with defined organelle/autophagic phenotype and independence from Akt-1 established by parallel controls; single lab","pmids":["17476689"],"is_preprint":false},{"year":2013,"finding":"PIM2 activity is required for phosphorylation of 4E-BP1 and BAD in liver cancer cells, and its kinase activity on these downstream mediators correlates with pro-survival functions.","method":"Pim-2 overexpression and knockdown in liver cancer cells, Western blot for phospho-4E-BP1 and phospho-BAD, IL-3 deprivation survival assay","journal":"The Journal of surgical research","confidence":"Low","confidence_rationale":"Tier 3 / Weak — indirect evidence from overexpression/knockdown correlating with phospho-substrates; no direct in vitro kinase assay; single lab; confirming known substrates in a new context","pmids":["18675992"],"is_preprint":false},{"year":2012,"finding":"The 34 kDa isoform of PIM-2 (but not the 41 kDa isoform) can, when N-terminally HA-tagged, induce G1 cell cycle arrest and apoptosis in HeLa cells in a kinase-dependent and p73-dependent manner, associated with increased T14/Y15 phosphorylation of CDK2, proteasome-dependent downregulation of CDC25A, and upregulation of p57, E2F-1, and p73.","method":"Transient overexpression with isoform-specific and kinase-dead constructs, flow cytometry, dominant-negative p73, p73 siRNA, Western blot","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — kinase-dead and dominant-negative controls, p73 genetic epistasis; single lab, single cell line; context-specific (HA-tagged 34 kDa form only)","pmids":["22506047"],"is_preprint":false},{"year":2013,"finding":"PIM-2 expression and activity increase upon UVC radiation in U2OS cells. PIM-2 accelerates removal of UV-induced DNA lesions, reduces γH2AX accumulation, and protects cells through increased E2F-1 and activated ATM levels. Epistasis places PIM-2 upstream of E2F-1 and ATM in the UV-damage response.","method":"PIM-2 silencing, overexpression, UV survival assay, γH2AX assay, E2F-1 siRNA, ATM kinase inhibition, DNA lesion removal assay","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis with E2F-1 and ATM, defined molecular phenotypes, multiple perturbations; single lab","pmids":["23760264"],"is_preprint":false},{"year":2017,"finding":"Pim-2 is identified as a novel RSK2-interacting upstream regulator in FLT3-ITD AML; ectopic RSK2 expression rescues viability of Pim2-depleted cells. Pim2 predominantly controls apoptosis through Bax expression and mitochondrial disruption in FLT3-ITD AML cells.","method":"Proteomics/transcriptomics in Pim2-depleted cells, ectopic RSK2 rescue, viability assays, Bax/mitochondria disruption analysis, in vivo mouse model","journal":"Leukemia","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic rescue epistasis, proteomic identification of target, in vivo validation; single lab","pmids":["28914261"],"is_preprint":false},{"year":2016,"finding":"Pim2 negatively regulates DNA damage response in multiple myeloma: Pim2 knockdown upregulates DDR markers mimicking doxorubicin treatment, placing Pim2 as a negative regulator of the DDR pathway downstream of doxorubicin-DNA binding. Doxorubicin treatment decreases Pim2 levels.","method":"shRNA knockdown of Pim2, doxorubicin treatment, Western blot for DDR markers, overexpression survival assay","journal":"Blood cancer journal","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — genetic knockdown with defined molecular DDR phenotype; single lab, limited mechanistic depth on direct substrate","pmids":["27564460"],"is_preprint":false},{"year":2015,"finding":"All three Pim2 isoforms localize to the cytoplasm in leukemic cells and are degraded by the proteasome without detectable ubiquitination—purified 20S proteasome particles degrade Pim2 in vitro. Pim2 mRNA accumulation is controlled by erythropoietin via STAT5; translation is not regulated by mTORC1.","method":"Subcellular fractionation, proteasome inhibitors (half-life analysis), E1 inhibitor Pyr41, in vitro 20S proteasome degradation assay, STAT5 inhibition, signaling pathway inhibitors","journal":"Bioscience reports","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution of ubiquitin-independent 20S proteasomal degradation, direct localization by fractionation, multiple pharmacological controls; single lab with multiple orthogonal methods","pmids":["26500282"],"is_preprint":false},{"year":2018,"finding":"PIM2 directly binds tristetraprolin (TTP) and promotes its proteasomal degradation independently of PIM2 kinase activity, thereby de-repressing TTP-mediated inhibition of breast cancer cell proliferation and migration.","method":"Co-immunoprecipitation, kinase-dead PIM2 mutant, ubiquitin-proteasome pathway assays, immunohistochemistry correlation, in vivo xenograft","journal":"Molecular oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — kinase-dead mutant distinguishes kinase-independent mechanism, Co-IP, proteasome assay, in vivo validation; single lab","pmids":["29570932"],"is_preprint":false},{"year":2014,"finding":"PIM2 inhibition reduces phosphorylation of 4E-BP1 (Thr37/46 and Ser65), establishing p4E-BP1 as a molecular biomarker of PIM2 kinase activity and indicating PIM2 involvement in regulating mTORC1.","method":"Pharmacological inhibition and genetic knockdown of PIM2, Western blot for phospho-4E-BP1, lymphoma cell lines","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — genetic plus pharmacological inhibition with consistent phospho-substrate readout; indirect evidence for mTORC1 regulation; multiple cell systems","pmids":["21937691"],"is_preprint":false},{"year":2019,"finding":"In CML stem cells (CMLSCs), PIM2 expression is maintained by both a BCR-ABL-dependent STAT5-mediated pathway and a BCR-ABL-independent STAT4-mediated pathway. PIM2 phosphorylates and inhibits BAD, contributing to imatinib resistance in CMLSCs.","method":"Single-cell RNA-seq, BCR-ABL identification, STAT4/STAT5 pathway analysis, BAD phosphorylation Western blot, mouse CML model, PIM inhibitor combined treatment","journal":"PNAS","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — single-cell genomics with pathway validation, in vivo mouse CML model, mechanistic assignment to two STAT pathways; single lab","pmids":["31068472"],"is_preprint":false},{"year":2016,"finding":"Pim-2 regulates osteoblastogenesis negatively; enforced expression abrogates BMP-2-induced osteoblastogenesis while Pim-2 inhibition or siRNA restores osteoblastogenesis. The inhibitor SMI-16a potentiates BMP-2 anabolic signaling while suppressing TGF-β signaling.","method":"siRNA knockdown, overexpression, SMI-16a inhibitor treatment, BMP-2-induced osteoblastogenesis assay, TGF-β/BMP signaling Western blot, in vivo MM animal model","journal":"Leukemia","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain and loss of function with defined signaling pathway readouts, in vivo validation; single lab","pmids":["24787487"],"is_preprint":false},{"year":2016,"finding":"PIM2 kinase sustains G1/S transition during plasmablast generation by acting on CDC25A and p27Kip1, and hinders caspase 3-driven apoptosis through BAD phosphorylation and cytoplasmic stabilization of p21Cip1.","method":"Morpholino antisense inhibition, pharmacological PIM inhibition, Western blot for CDC25A/p27Kip1/BAD phosphorylation/p21Cip1, flow cytometry for cell cycle and apoptosis","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Moderate — novel morpholino antisense strategy plus pharmacological inhibition with multiple defined molecular targets; consistent with known PIM2 substrate biology; single lab","pmids":["35108359"],"is_preprint":false},{"year":2021,"finding":"PIM2 directly phosphorylates PFKFB3 at Ser478, enhancing PFKFB3 protein stability through the ubiquitin-proteasome pathway, which promotes glycolysis, BC cell growth, and paclitaxel resistance.","method":"Mass spectrometry, co-immunoprecipitation, in vitro kinase assay, PFKFB3 site-specific mutants, ubiquitination assay, xenograft model","journal":"Clinical and translational medicine","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct in vitro kinase assay with site-specific mutant, ubiquitination pathway assay, in vivo validation; single lab with multiple orthogonal methods","pmids":["33931981"],"is_preprint":false},{"year":2022,"finding":"PIM2 directly phosphorylates PFKFB4 on Thr140 and enhances PFKFB4 protein expression through the ubiquitin-proteasome pathway, promoting glycolysis and cell growth in endometriosis.","method":"Co-immunoprecipitation, in vitro kinase assay, site-directed mutagenesis, ubiquitin-proteasome assay, in vivo endometriosis model","journal":"Cell death & disease","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct in vitro kinase assay with mutagenesis, ubiquitination pathway validation, in vivo model; single lab","pmids":["36109523"],"is_preprint":false},{"year":2016,"finding":"PIM-2 isoform negatively regulates T cell responses to alloantigen (unlike PIM-1 and PIM-3, which are positive regulators); PIM-2-deficient T cells show increased Th1 differentiation, proliferation, and migration, leading to accelerated GVHD; PIM-2 also suppresses CD8+ T cell antitumor responses.","method":"Pim-2 genetic knockout mice, allogeneic bone marrow transplantation model, syngeneic tumor rejection model, adoptive T cell transfer, flow cytometry, rescue expression experiments","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO with rescue expression, multiple in vivo models (GVHD, tumor rejection, adoptive transfer), isoform-specific functional distinction from PIM-1/3; single lab with multiple orthogonal approaches","pmids":["29781812"],"is_preprint":false},{"year":2019,"finding":"TRAF3 deficiency induces Pim2 upregulation in B cells via STAT3 (independent of NF-κB2), and elevated Pim2 in turn increases c-Myc protein levels with reduced c-Myc ubiquitination.","method":"TRAF3 knockout B cells, STAT3 inhibition, Pim inhibitor treatment, c-Myc ubiquitination assay, Western blot","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — TRAF3 KO and STAT3 inhibition epistasis, ubiquitination assay; single lab","pmids":["31501481"],"is_preprint":false},{"year":2016,"finding":"PIM2 kinase phosphorylates the serine/threonine kinase Bim on Ser65, promotes its proteasomal degradation, and protects H9c2 cardiomyocytes from hypoxia/reoxygenation-induced apoptosis. A Bim S65A mutation reverses the anti-apoptotic role of Pim-2.","method":"Co-immunoprecipitation (Pim-2/Bim interaction), site-directed mutagenesis (Bim S65A), proteasome inhibitor MG132, overexpression and siRNA, Western blot for Cyt C","journal":"Environmental toxicology and pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP for interaction, mutagenesis for phosphorylation site, proteasome assay; single lab, single cell line","pmids":["27770661"],"is_preprint":false},{"year":2017,"finding":"PIM2 directly phosphorylates PGK1 at Ser203, PDHA1 at Ser300, and PFKFB2 at Ser466, promoting glycolytic reprogramming during M1 macrophage polarization and inflammatory arthritis.","method":"Conditional macrophage-specific Pim2 knockout, in vitro kinase assays (implied by direct phosphorylation claim and biochemical analyses), glycolytic assays, CIA arthritis model","journal":"Cellular & molecular immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo conditional KO with defined metabolic phenotype, direct phosphorylation sites identified; single lab, abstract does not explicitly state reconstituted in vitro assay","pmids":["40000906"],"is_preprint":false},{"year":2020,"finding":"PIM2 activates NF-κB signaling in hepatocellular carcinoma by upregulating phosphorylation of RIPK2. TNFα induces PIM2 expression, and PIM2 in turn upregulates TNFα, forming a positive feedback loop.","method":"Functional studies with overexpression/knockdown, Western blot for phospho-RIPK2, NF-κB reporter, TNFα stimulation experiments, in vivo xenograft","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — phosphorylation of RIPK2 by PIM2 is inferred from expression manipulation without direct in vitro kinase assay; single lab","pmids":["32641749"],"is_preprint":false},{"year":2020,"finding":"PIM2 directly interacts with NLRP3 and promotes LPS-triggered NLRP3 inflammasome activation (Caspase-1, IL-1β) in macrophages; Pim2 knockout significantly alleviated ARDS in LPS-challenged mice.","method":"Co-immunoprecipitation, PIM2 overexpression and knockdown, Pim2 knockout mice, ARDS mouse model, inflammasome component Western blot","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP for direct interaction, genetic KO in vivo; no in vitro kinase assay for direct phosphorylation of NLRP3; single lab","pmids":["33333710"],"is_preprint":false},{"year":2020,"finding":"PIM2 phosphorylates FBP1 on Ser144, abrogating FBP1 interaction with NF-κB p65 and promoting p65 stability through the CHIP-mediated proteasome pathway, leading to increased PD-L1 expression and breast tumor growth.","method":"Immunoaffinity purification, co-immunoprecipitation, in vitro kinase assay, ubiquitination/proteasome assay, PIM2 KO mice, in vivo xenograft","journal":"Theranostics","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct in vitro kinase assay, Co-IP, ubiquitination assay, KO mouse model; single lab with multiple orthogonal methods","pmids":["32754266"],"is_preprint":false},{"year":2014,"finding":"A regulatory feedback loop exists between HIF-1α and PIM2: HIF-1α induces PIM2 expression by binding hypoxia-responsive elements (HREs) in the PIM2 promoter, and PIM2 in turn interacts with HIF-1α (at its transactivation domain) as a co-factor (not a kinase) to enhance HIF-1α transcriptional activity.","method":"ChIP for HRE binding, co-immunoprecipitation of PIM2/HIF-1α, domain-mapping, glucose metabolism assay, hypoxia experiments","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and Co-IP with domain mapping; single lab; notable finding that PIM2 acts as co-factor not kinase for HIF-1α","pmids":["24505470"],"is_preprint":false},{"year":2022,"finding":"PIM2 inhibition reduces phosphorylated BAD production and activates ISR-mediated NOXA expression, shifting plasma cells to MCL1 dependence. Combined PIM/MCL1 inhibition synergistically controls tumor growth, and ISR-specific inhibition reverses this synergy.","method":"PIM2 inhibition, MCL1 inhibitor, ISR inhibitor (genetic and pharmacological), Western blot for phospho-BAD and NOXA, xenograft mouse model","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological and genetic inhibition with defined downstream signaling (ISR/NOXA), in vivo xenograft, multiple perturbations; single lab","pmids":["39747141"],"is_preprint":false},{"year":2017,"finding":"PIM2 regulates stemness in embryonic stem cells by directly phosphorylating 4E-BP1, leading to eIF4E release and facilitated translation of pluripotent genes. Pim2 knockout inhibits ESC self-renewal and differentiation capability.","method":"Pim2 knockout, in vitro kinase assay for 4E-BP1 phosphorylation, eIF4E cap-binding assay, self-renewal and differentiation assays","journal":"Science bulletin","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — in vitro kinase assay and KO phenotype in ESCs; single lab, single study","pmids":["36659438"],"is_preprint":false},{"year":2024,"finding":"PIM2 phosphorylates USP27X, promoting USP27X deubiquitylase activity toward MYC, thereby stabilizing MYC protein and increasing HK2-mediated aerobic glycolysis in breast cancer. This PIM2-USP27X-MYC axis is validated in PIM2-knockout mice.","method":"Co-immunoprecipitation, in vitro kinase assay, deubiquitylation assay, MYC stability Western blot, glycolysis assay, PIM2 KO mouse model","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct kinase assay, functional deubiquitylation assay, KO mouse validation; single lab with multiple orthogonal methods","pmids":["38969771"],"is_preprint":false},{"year":2022,"finding":"Pim-2 regulates osteoclastic bone resorption activity by controlling expression of the V-ATPase a3 isoform; Pim-2 siRNA silencing diminishes RANKL-induced resorptive activity and attenuates RANKL-triggered a3 stimulation without affecting osteoclast differentiation. Pim-2 overexpression stimulates a3 subunit expression and induces bone resorption.","method":"siRNA silencing and retroviral overexpression in BMMs, RANKL-induced osteoclastogenesis, dentin bone resorption assay, RT-PCR/Western blot for a3 isoform","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain and loss of function with defined molecular target (a3 isoform) and functional bone resorption readout; single lab","pmids":["35696529"],"is_preprint":false},{"year":2018,"finding":"p53 activation (via actinomycin D + nutlin-3a) leads to accumulation of PIM2 in a p53-dependent manner (abrogated by p53 knockdown), which then phosphorylates BAD on Ser136, providing an inactivating (pro-survival) signal concurrent with p53-induced apoptosis.","method":"Antibody arrays for apoptotic proteins, Western blot for phospho-BAD, p53 knockdown, A549 cells","journal":"Archives of biochemistry and biophysics","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — p53 dependency established by KD, phospho-BAD as PIM2 substrate inferred rather than directly assayed; single lab","pmids":["30096294"],"is_preprint":false}],"current_model":"PIM2 is a constitutively active serine/threonine kinase whose activity is primarily regulated at the transcriptional level (downstream of cytokines via JAK/STAT5 and NF-κB, and by p53 and HIF-1α) and post-translationally through ubiquitin-independent 20S proteasomal degradation; it promotes cell survival and proliferation by directly phosphorylating a broad set of substrates—including BAD (Ser112), 4E-BP1, TSC2 (Ser1798), p21(Thr145), Bim (Ser65), HK2 (Thr473), PKM2 (Thr454), AMPKα1 (Thr467), HSF1 (Thr120), FBP1 (Ser144), PFKFB3 (Ser478), PFKFB4 (Thr140), PGK1 (Ser203), PDHA1 (Ser300), PFKFB2 (Ser466), and USP27X—thereby integrating anti-apoptotic signaling (via BAD, Bim, Bcl-2 family), mTORC1 activation (via TSC2), translational control (via 4E-BP1/eIF4E), Warburg-effect glycolysis, NF-κB activation (via Cot/IKK), immune regulation (via Foxp3 in Tregs and T cell responses), DNA damage response, and NLRP3 inflammasome activation into a unified pro-survival and oncogenic program."},"narrative":{"mechanistic_narrative":"PIM2 is a constitutively active, cytoplasmic serine/threonine kinase that integrates cytokine and stress signaling into a coordinated pro-survival, pro-proliferative, and metabolic program, with broad oncogenic consequences [PMID:12869584, PMID:7781606]. Its central survival output is phosphorylation and inactivation of the pro-apoptotic BH3 protein BAD (Ser112) together with rapamycin-resistant phosphorylation of the translational repressor 4E-BP1, sustaining cell survival, cell size, and mitochondrial potential independently of PI3K/Akt/TOR [PMID:12869584, PMID:12954615]. PIM2 reinforces apoptotic resistance through additional substrates—phosphorylating Bim (Ser65) to drive its proteasomal degradation [PMID:27770661] and stabilizing p21 via Thr145 phosphorylation [PMID:20307683]—and it couples survival to mTORC1 activation by directly phosphorylating TSC2 (Ser1798) to relieve its suppression of mTOR-C1 [PMID:23818547]. A second major axis is glycolytic (Warburg) reprogramming: PIM2 binds and phosphorylates hexokinase-2 (Thr473), PKM2 (Thr454), and inhibits AMPKα1 (Thr467), and phosphorylates PFKFB3 (Ser478) and PFKFB4 (Thr140) to stabilize them through the ubiquitin-proteasome pathway, collectively enhancing aerobic glycolysis and tumor growth [PMID:29985480, PMID:24142698, PMID:31358902, PMID:33931981, PMID:36109523]. PIM2 also activates NF-κB signaling by phosphorylating and activating Cot, which augments IκB kinase activity, an event required for PIM2-mediated survival and oncogenesis [PMID:15548703]. Beyond canonical kinase activity, PIM2 functions kinase-independently—degrading tristetraprolin to de-repress proliferation [PMID:29570932] and acting as a transcriptional co-factor for HIF-1α [PMID:24505470]—and it has context-specific immunoregulatory roles, phosphorylating Foxp3 to weaken Treg suppression [PMID:25987564] and negatively regulating alloreactive T cell responses [PMID:29781812]. PIM2 itself is regulated transcriptionally downstream of JAK/STAT5 and STAT3/STAT4, p53, HIF-1α, and CHES1/FOXN3, and post-translationally by ubiquitin-independent degradation by the 20S proteasome [PMID:26500282, PMID:24403608, PMID:24505470, PMID:30096294, PMID:31068472].","teleology":[{"year":1995,"claim":"Established PIM2 as a distinct kinase functionally redundant with PIM1, placing it within the same oncogenic pathway and explaining why it can substitute for PIM1 loss.","evidence":"PCR-based gene identification and proviral complementation tagging in Eµ-myc/Pim-1−/− mice","pmids":["7781606"],"confidence":"High","gaps":["Did not define direct substrates","Mechanism of constitutive activity not addressed"]},{"year":2003,"claim":"Defined PIM2's core survival mechanism: direct phosphorylation of BAD (Ser112) and rapamycin-resistant 4E-BP1 phosphorylation, establishing a PI3K/Akt/TOR-independent survival pathway.","evidence":"Constitutive expression in hematopoietic/FDCP1 cells, in vitro kinase assay, growth-factor withdrawal survival assays","pmids":["12869584","12954615"],"confidence":"High","gaps":["Mechanism by which 4E-BP1 phosphorylation is maintained not resolved","Relative contribution of three isoforms to physiological survival unclear"]},{"year":2004,"claim":"Showed PIM2-driven survival and oncogenesis require NF-κB, placing PIM2 upstream of the Cot/IKK/NF-κB axis.","evidence":"Reporter assays, Co-IP, NF-κB blockade, primary cell rescue, in vivo lymphoma model","pmids":["15548703"],"confidence":"High","gaps":["Direct phosphorylation site on Cot not mapped","Whether NF-κB activation is universal across PIM2 contexts unknown"]},{"year":2009,"claim":"Provided structural basis for PIM2 inhibition, revealing ATP-pocket differences from PIM1 exploitable for isoform-selective inhibitors.","evidence":"X-ray crystallography of PIM2 with an organoruthenium inhibitor","pmids":["19841674"],"confidence":"High","gaps":["No substrate-bound structure","Basis of constitutive activity not structurally explained"]},{"year":2013,"claim":"Connected PIM2 to mTORC1 and Warburg metabolism via direct phosphorylation of TSC2 (Ser1798) and PKM2 (Thr454), extending its function beyond survival into proliferation and glycolysis.","evidence":"In vitro kinase assays, knockdown/inhibitor, phospho-defective mutants, glycolysis assays in MM and other cells","pmids":["23818547","24142698"],"confidence":"High","gaps":["Crosstalk between TSC2/mTORC1 and direct 4E-BP1 phosphorylation not disentangled","In vivo metabolic consequences only partially characterized"]},{"year":2015,"claim":"Defined PIM2's post-translational regulation and immunoregulatory role: ubiquitin-independent 20S proteasomal degradation, STAT5-controlled mRNA, and Foxp3 phosphorylation weakening Treg suppression.","evidence":"In vitro 20S degradation reconstitution, fractionation, STAT5 inhibition; in vitro Foxp3 kinase assay with Treg knockout and colitis model","pmids":["26500282","25987564"],"confidence":"High","gaps":["Degron motif targeting PIM2 to 20S proteasome not defined","Foxp3 phosphosites and their individual contributions incompletely mapped"]},{"year":2018,"claim":"Revealed a kinase-independent mode of action—PIM2 degrades tristetraprolin to de-repress proliferation—and a metabolic axis stabilizing HK2 via chaperone-mediated autophagy.","evidence":"Co-IP, kinase-dead mutants, proteasome/CMA assays, in vitro kinase assay (HK2 Thr473), xenografts","pmids":["29570932","29985480"],"confidence":"High","gaps":["How a kinase mediates substrate degradation without phosphorylation is mechanistically unresolved","Determinants choosing kinase-dependent vs -independent outputs unknown"]},{"year":2019,"claim":"Extended the glycolytic and immune-evasion network: PIM2 inhibits AMPKα1 (Thr467), and stabilizes HSF1 (Thr120) to drive PD-L1 expression.","evidence":"In vitro kinase assays with site mutants, ChIP, KO mouse and xenograft models","pmids":["31358902","31409638"],"confidence":"High","gaps":["Integration of multiple metabolic substrates into a single flux model lacking","PD-L1 immune-evasion consequence not tested in immunocompetent tumor settings here"]},{"year":2020,"claim":"Linked PIM2 to NF-κB stabilization and innate immunity: phosphorylation of FBP1 (Ser144) stabilizing p65/PD-L1, and direct binding to NLRP3 promoting inflammasome activation.","evidence":"In vitro kinase/ubiquitination assays, Co-IP, PIM2 KO mice, ARDS model","pmids":["32754266","33333710"],"confidence":"Medium","gaps":["Whether NLRP3 is a direct phosphorylation substrate not established","RIPK2 phosphorylation (idx 35) inferred without in vitro kinase assay"]},{"year":2021,"claim":"Consolidated PIM2 as a master glycolytic regulator stabilizing PFKFB3 (Ser478) and PFKFB4 (Thr140) via the ubiquitin-proteasome pathway across cancer and endometriosis.","evidence":"Mass spectrometry, in vitro kinase assays with site mutants, ubiquitination assays, xenograft/in vivo models","pmids":["33931981","36109523"],"confidence":"High","gaps":["Common mechanism by which phosphorylation blocks ubiquitination across these substrates not unified","Tissue specificity of substrate selection unclear"]},{"year":2024,"claim":"Identified a PIM2-USP27X-MYC axis in which PIM2 phosphorylation of USP27X stabilizes MYC to boost HK2-driven glycolysis, integrating deubiquitination control into PIM2's metabolic program.","evidence":"Co-IP, in vitro kinase assay, deubiquitylation assay, MYC stability and glycolysis assays, PIM2 KO mice","pmids":["38969771"],"confidence":"High","gaps":["USP27X phosphosite not specified in the finding","Relationship to direct HK2 phosphorylation pathway not reconciled"]},{"year":null,"claim":"How PIM2's many parallel substrate axes (survival, mTORC1, glycolysis, NF-κB, immune regulation) are prioritized in a given cell type, and what governs its kinase-dependent versus kinase-independent and co-factor functions, remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model of substrate selection across tissues","Determinants of kinase-independent vs catalytic activity undefined","Structural basis of constitutive activity and isoform-specific functions incompletely understood"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,1,4,6,9,11,12,29,30,33,34,37,41]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[1,4,6,9,11,29,30,37]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[38]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[11,24]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[23]}],"pathway":[{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[0,1,33,39,43]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[6,9,11,29,30,34,41]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[3,4,35]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[7,31,36]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[12,19,28]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[23,24,29,30,37]}],"complexes":[],"partners":["BAD","TSC2","HK2","PKM2","PRKAA1","HSF1","HIF1A","NLRP3"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9P1W9","full_name":"Serine/threonine-protein kinase pim-2","aliases":["Pim-2h"],"length_aa":311,"mass_kda":34.2,"function":"Proto-oncogene with serine/threonine kinase activity involved in cell survival and cell proliferation. Exerts its oncogenic activity through: the regulation of MYC transcriptional activity, the regulation of cell cycle progression, the regulation of cap-dependent protein translation and through survival signaling by phosphorylation of a pro-apoptotic protein, BAD. Phosphorylation of MYC leads to an increase of MYC protein stability and thereby an increase transcriptional activity. The stabilization of MYC exerted by PIM2 might explain partly the strong synergism between these 2 oncogenes in tumorigenesis. Regulates cap-dependent protein translation in a mammalian target of rapamycin complex 1 (mTORC1)-independent manner and in parallel to the PI3K-Akt pathway. Mediates survival signaling through phosphorylation of BAD, which induces release of the anti-apoptotic protein Bcl-X(L)/BCL2L1. Promotes cell survival in response to a variety of proliferative signals via positive regulation of the I-kappa-B kinase/NF-kappa-B cascade; this process requires phosphorylation of MAP3K8/COT. Promotes growth factor-independent proliferation by phosphorylation of cell cycle factors such as CDKN1A and CDKN1B. Involved in the positive regulation of chondrocyte survival and autophagy in the epiphyseal growth plate","subcellular_location":"","url":"https://www.uniprot.org/uniprotkb/Q9P1W9/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/PIM2","classification":"Not Classified","n_dependent_lines":44,"n_total_lines":1208,"dependency_fraction":0.03642384105960265},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/PIM2","total_profiled":1310},"omim":[{"mim_id":"610580","title":"ONCOGENE PIM3; PIM3","url":"https://www.omim.org/entry/610580"},{"mim_id":"300295","title":"PIM2 PROTOONCOGENE, SERINE/THREONINE KINASE; PIM2","url":"https://www.omim.org/entry/300295"},{"mim_id":"164960","title":"ONCOGENE PIM 1; PIM1","url":"https://www.omim.org/entry/164960"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Cytosol","reliability":"Approved"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"bone marrow","ntpm":96.5},{"tissue":"intestine","ntpm":82.3},{"tissue":"lymphoid tissue","ntpm":152.7}],"url":"https://www.proteinatlas.org/search/PIM2"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"Q9P1W9","domains":[{"cath_id":"3.30.200.20","chopping":"24-116","consensus_level":"high","plddt":94.4776,"start":24,"end":116},{"cath_id":"1.10.510.10","chopping":"121-286","consensus_level":"high","plddt":97.7846,"start":121,"end":286}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9P1W9","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9P1W9-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9P1W9-F1-predicted_aligned_error_v6.png","plddt_mean":89.62},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=PIM2","jax_strain_url":"https://www.jax.org/strain/search?query=PIM2"},"sequence":{"accession":"Q9P1W9","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9P1W9.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9P1W9/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9P1W9"}},"corpus_meta":[{"pmid":"12869584","id":"PMC_12869584","title":"The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor.","date":"2003","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/12869584","citation_count":282,"is_preprint":false},{"pmid":"12954615","id":"PMC_12954615","title":"The PIM-2 kinase phosphorylates BAD on serine 112 and reverses BAD-induced cell death.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12954615","citation_count":236,"is_preprint":false},{"pmid":"7781606","id":"PMC_7781606","title":"Proviral tagging in E mu-myc transgenic mice lacking the Pim-1 proto-oncogene leads to compensatory activation of Pim-2.","date":"1995","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/7781606","citation_count":167,"is_preprint":false},{"pmid":"19072652","id":"PMC_19072652","title":"Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases.","date":"2009","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19072652","citation_count":148,"is_preprint":false},{"pmid":"23818547","id":"PMC_23818547","title":"Pim2 is required for maintaining multiple myeloma cell growth through modulating TSC2 phosphorylation.","date":"2013","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/23818547","citation_count":138,"is_preprint":false},{"pmid":"9294606","id":"PMC_9294606","title":"Pim-2 transgene induces lymphoid tumors, exhibiting potent synergy with c-myc.","date":"1997","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/9294606","citation_count":138,"is_preprint":false},{"pmid":"29985480","id":"PMC_29985480","title":"PIM2-mediated phosphorylation of hexokinase 2 is critical for tumor growth and paclitaxel resistance in breast cancer.","date":"2018","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/29985480","citation_count":114,"is_preprint":false},{"pmid":"21475253","id":"PMC_21475253","title":"The serine/threonine kinase Pim-2 is a novel anti-apoptotic mediator in myeloma cells.","date":"2011","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/21475253","citation_count":96,"is_preprint":false},{"pmid":"2721500","id":"PMC_2721500","title":"Evidence for the involvement of pim-2, a new common proviral insertion site, in progression of lymphomas.","date":"1989","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/2721500","citation_count":93,"is_preprint":false},{"pmid":"21937691","id":"PMC_21937691","title":"PIM2 inhibition as a rational therapeutic approach in B-cell lymphoma.","date":"2011","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/21937691","citation_count":91,"is_preprint":false},{"pmid":"22727640","id":"PMC_22727640","title":"Discovery of novel benzylidene-1,3-thiazolidine-2,4-diones as potent and selective inhibitors of the PIM-1, PIM-2, and PIM-3 protein kinases.","date":"2012","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/22727640","citation_count":83,"is_preprint":false},{"pmid":"15548703","id":"PMC_15548703","title":"Lymphocyte transformation by Pim-2 is dependent on nuclear factor-kappaB activation.","date":"2004","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/15548703","citation_count":82,"is_preprint":false},{"pmid":"24142698","id":"PMC_24142698","title":"Proviral insertion in murine lymphomas 2 (PIM2) oncogene phosphorylates pyruvate kinase M2 (PKM2) and promotes glycolysis in cancer cells.","date":"2013","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24142698","citation_count":77,"is_preprint":false},{"pmid":"25987564","id":"PMC_25987564","title":"Pim-2 Kinase Influences Regulatory T Cell Function and Stability by Mediating Foxp3 Protein N-terminal Phosphorylation.","date":"2015","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25987564","citation_count":76,"is_preprint":false},{"pmid":"31409638","id":"PMC_31409638","title":"Phosphorylation of HSF1 by PIM2 Induces PD-L1 Expression and Promotes Tumor Growth in Breast Cancer.","date":"2019","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/31409638","citation_count":75,"is_preprint":false},{"pmid":"19841674","id":"PMC_19841674","title":"Crystal structure of the PIM2 kinase in complex with an organoruthenium inhibitor.","date":"2009","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/19841674","citation_count":72,"is_preprint":false},{"pmid":"16015593","id":"PMC_16015593","title":"Pim-2 upregulation: biological implications associated with disease progression and perinueral invasion in prostate cancer.","date":"2005","source":"The Prostate","url":"https://pubmed.ncbi.nlm.nih.gov/16015593","citation_count":66,"is_preprint":false},{"pmid":"18042805","id":"PMC_18042805","title":"Pim-1 and Pim-2 kinases are required for efficient pre-B-cell transformation by v-Abl oncogene.","date":"2007","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/18042805","citation_count":66,"is_preprint":false},{"pmid":"24659821","id":"PMC_24659821","title":"PIM kinases are essential for chronic lymphocytic leukemia cell survival (PIM2/3) and CXCR4-mediated microenvironmental interactions (PIM1).","date":"2014","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/24659821","citation_count":59,"is_preprint":false},{"pmid":"24787487","id":"PMC_24787487","title":"Pim-2 kinase is an important target of treatment for tumor progression and bone loss in myeloma.","date":"2014","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/24787487","citation_count":55,"is_preprint":false},{"pmid":"33931981","id":"PMC_33931981","title":"Positive regulation of PFKFB3 by PIM2 promotes glycolysis and paclitaxel resistance in breast cancer.","date":"2021","source":"Clinical and translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33931981","citation_count":54,"is_preprint":false},{"pmid":"18790640","id":"PMC_18790640","title":"Isoxazolo[3,4-b]quinoline-3,4(1H,9H)-diones as unique, potent and selective inhibitors for Pim-1 and Pim-2 kinases: chemistry, biological activities, and molecular modeling.","date":"2008","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/18790640","citation_count":50,"is_preprint":false},{"pmid":"19290049","id":"PMC_19290049","title":"PIM2 Induced COX-2 and MMP-9 expression in macrophages requires PI3K and Notch1 signaling.","date":"2009","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/19290049","citation_count":49,"is_preprint":false},{"pmid":"36109523","id":"PMC_36109523","title":"Phosphorylation of PFKFB4 by PIM2 promotes anaerobic glycolysis and cell proliferation in endometriosis.","date":"2022","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/36109523","citation_count":44,"is_preprint":false},{"pmid":"22201128","id":"PMC_22201128","title":"RAG-induced DNA double-strand breaks signal through Pim2 to promote pre-B cell survival and limit proliferation.","date":"2011","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22201128","citation_count":43,"is_preprint":false},{"pmid":"25854938","id":"PMC_25854938","title":"Persistent activation of STAT3 by PIM2-driven positive feedback loop for epithelial-mesenchymal transition in breast cancer.","date":"2015","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/25854938","citation_count":42,"is_preprint":false},{"pmid":"19821157","id":"PMC_19821157","title":"Pim-2 activates API-5 to inhibit the apoptosis of hepatocellular carcinoma cells through NF-kappaB pathway.","date":"2009","source":"Pathology oncology research : POR","url":"https://pubmed.ncbi.nlm.nih.gov/19821157","citation_count":40,"is_preprint":false},{"pmid":"21945284","id":"PMC_21945284","title":"Discovery of novel 3,5-disubstituted indole derivatives as potent inhibitors of Pim-1, Pim-2, and Pim-3 protein kinases.","date":"2011","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/21945284","citation_count":40,"is_preprint":false},{"pmid":"31358902","id":"PMC_31358902","title":"Negative regulation of AMPKα1 by PIM2 promotes aerobic glycolysis and tumorigenesis in endometrial cancer.","date":"2019","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/31358902","citation_count":38,"is_preprint":false},{"pmid":"9804974","id":"PMC_9804974","title":"The human Pim-2 proto-oncogene and its testicular expression.","date":"1998","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/9804974","citation_count":37,"is_preprint":false},{"pmid":"28008178","id":"PMC_28008178","title":"Novel inhibition of PIM2 kinase has significant anti-tumor efficacy in multiple myeloma.","date":"2016","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/28008178","citation_count":36,"is_preprint":false},{"pmid":"24403608","id":"PMC_24403608","title":"CHES1/FOXN3 regulates cell proliferation by repressing PIM2 and protein biosynthesis.","date":"2014","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/24403608","citation_count":35,"is_preprint":false},{"pmid":"20307683","id":"PMC_20307683","title":"Pim-2 phosphorylation of p21(Cip1/WAF1) enhances its stability and inhibits cell proliferation in HCT116 cells.","date":"2010","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/20307683","citation_count":35,"is_preprint":false},{"pmid":"27901106","id":"PMC_27901106","title":"The role of PIM1/PIM2 kinases in tumors of the male reproductive system.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27901106","citation_count":34,"is_preprint":false},{"pmid":"33854618","id":"PMC_33854618","title":"Protein kinase PIM2: A simple PIM family kinase with complex functions in cancer metabolism and therapeutics.","date":"2021","source":"Journal of Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/33854618","citation_count":33,"is_preprint":false},{"pmid":"29781812","id":"PMC_29781812","title":"PIM-2 protein kinase negatively regulates T cell responses in transplantation and tumor immunity.","date":"2018","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/29781812","citation_count":33,"is_preprint":false},{"pmid":"17476689","id":"PMC_17476689","title":"PIM-2 is an independent regulator of chondrocyte survival and autophagy in the epiphyseal growth plate.","date":"2007","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/17476689","citation_count":33,"is_preprint":false},{"pmid":"18675992","id":"PMC_18675992","title":"Serine/threonine kinase Pim-2 promotes liver tumorigenesis induction through mediating survival and preventing apoptosis of liver cell.","date":"2008","source":"The Journal of surgical research","url":"https://pubmed.ncbi.nlm.nih.gov/18675992","citation_count":33,"is_preprint":false},{"pmid":"40000906","id":"PMC_40000906","title":"Targeting macrophage polarization by inhibiting Pim2 alleviates inflammatory arthritis via metabolic reprogramming.","date":"2025","source":"Cellular & molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/40000906","citation_count":31,"is_preprint":false},{"pmid":"32641749","id":"PMC_32641749","title":"PIM2 promotes hepatocellular carcinoma tumorigenesis and progression through activating NF-κB signaling pathway.","date":"2020","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/32641749","citation_count":31,"is_preprint":false},{"pmid":"22205266","id":"PMC_22205266","title":"Antimyeloma activity of the sesquiterpene lactone cnicin: impact on Pim-2 kinase as a novel therapeutic target.","date":"2011","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/22205266","citation_count":29,"is_preprint":false},{"pmid":"17943165","id":"PMC_17943165","title":"Pim2 complements Flt3 wild-type receptor in hematopoietic progenitor cell transformation.","date":"2007","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/17943165","citation_count":28,"is_preprint":false},{"pmid":"28914261","id":"PMC_28914261","title":"RSK2 is a new Pim2 target with pro-survival functions in FLT3-ITD-positive acute myeloid leukemia.","date":"2017","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/28914261","citation_count":28,"is_preprint":false},{"pmid":"26643319","id":"PMC_26643319","title":"Loss of PIM2 enhances the anti-proliferative effect of the pan-PIM kinase inhibitor AZD1208 in non-Hodgkin lymphomas.","date":"2015","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/26643319","citation_count":26,"is_preprint":false},{"pmid":"29570932","id":"PMC_29570932","title":"PIM2 interacts with tristetraprolin and promotes breast cancer tumorigenesis.","date":"2018","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/29570932","citation_count":25,"is_preprint":false},{"pmid":"34511042","id":"PMC_34511042","title":"Long non-coding RNA SOX21-AS1 modulates lung cancer progress upon microRNA miR-24-3p/PIM2 axis.","date":"2021","source":"Bioengineered","url":"https://pubmed.ncbi.nlm.nih.gov/34511042","citation_count":25,"is_preprint":false},{"pmid":"26078709","id":"PMC_26078709","title":"Pim-2 Modulates Aerobic Glycolysis and Energy Production during the Development of Colorectal Tumors.","date":"2015","source":"International journal of medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/26078709","citation_count":25,"is_preprint":false},{"pmid":"25099161","id":"PMC_25099161","title":"PIM2 kinase is induced by cisplatin in ovarian cancer cells and limits drug efficacy.","date":"2014","source":"Journal of proteome research","url":"https://pubmed.ncbi.nlm.nih.gov/25099161","citation_count":24,"is_preprint":false},{"pmid":"28938604","id":"PMC_28938604","title":"Inflammation and stem markers association to PIM1/PIM2 kinase-induced tumors in breast and uterus.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28938604","citation_count":24,"is_preprint":false},{"pmid":"30593845","id":"PMC_30593845","title":"MicroRNA-26b-5p enhances T cell responses by targeting PIM-2 in hepatocellular carcinoma.","date":"2018","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/30593845","citation_count":24,"is_preprint":false},{"pmid":"26500282","id":"PMC_26500282","title":"Control of Pim2 kinase stability and expression in transformed human haematopoietic cells.","date":"2015","source":"Bioscience reports","url":"https://pubmed.ncbi.nlm.nih.gov/26500282","citation_count":23,"is_preprint":false},{"pmid":"35802648","id":"PMC_35802648","title":"PIM2 Expression Induced by Proinflammatory Macrophages Suppresses Immunotherapy Efficacy in Hepatocellular Carcinoma.","date":"2022","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/35802648","citation_count":22,"is_preprint":false},{"pmid":"23813671","id":"PMC_23813671","title":"The over-expression of Pim-2 promote the tumorigenesis of prostatic carcinoma through phosphorylating eIF4B.","date":"2013","source":"The Prostate","url":"https://pubmed.ncbi.nlm.nih.gov/23813671","citation_count":22,"is_preprint":false},{"pmid":"32754266","id":"PMC_32754266","title":"Fructose-1, 6-bisphosphatase 1 interacts with NF-κB p65 to regulate breast tumorigenesis via PIM2 induced phosphorylation.","date":"2020","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/32754266","citation_count":21,"is_preprint":false},{"pmid":"24505470","id":"PMC_24505470","title":"A regulatory feedback loop between HIF-1α and PIM2 in HepG2 cells.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24505470","citation_count":21,"is_preprint":false},{"pmid":"37059967","id":"PMC_37059967","title":"PIM2 Promotes the Development of Ovarian Endometriosis by Enhancing Glycolysis and Fibrosis.","date":"2023","source":"Reproductive sciences (Thousand Oaks, Calif.)","url":"https://pubmed.ncbi.nlm.nih.gov/37059967","citation_count":20,"is_preprint":false},{"pmid":"27564460","id":"PMC_27564460","title":"Pim2 is important for regulating DNA damage response in multiple myeloma cells.","date":"2016","source":"Blood cancer journal","url":"https://pubmed.ncbi.nlm.nih.gov/27564460","citation_count":20,"is_preprint":false},{"pmid":"19608279","id":"PMC_19608279","title":"SOCS3 expression induced by PIM2 requires PKC and PI3K signaling.","date":"2009","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/19608279","citation_count":20,"is_preprint":false},{"pmid":"22506047","id":"PMC_22506047","title":"Activation of cell cycle arrest and apoptosis by the proto-oncogene Pim-2.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22506047","citation_count":20,"is_preprint":false},{"pmid":"35026522","id":"PMC_35026522","title":"Abrine promotes cell proliferation and inhibits apoptosis of interleukin-1β-stimulated chondrocytes via PIM2/VEGF signalling in osteoarthritis.","date":"2021","source":"Phytomedicine : international journal of phytotherapy and phytopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/35026522","citation_count":19,"is_preprint":false},{"pmid":"31894300","id":"PMC_31894300","title":"Inhibition of PIM2 in liver cancer decreases tumor cell proliferation in vitro and in vivo primarily through the modulation of cell cycle progression.","date":"2019","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/31894300","citation_count":19,"is_preprint":false},{"pmid":"29541172","id":"PMC_29541172","title":"Downregulation of Pim-2 induces cell cycle arrest in the G0/G1 phase via the p53-non-dependent p21 signaling pathway.","date":"2018","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/29541172","citation_count":18,"is_preprint":false},{"pmid":"35108359","id":"PMC_35108359","title":"PIM2 kinase has a pivotal role in plasmablast generation and plasma cell survival, opening up novel treatment options in myeloma.","date":"2022","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/35108359","citation_count":17,"is_preprint":false},{"pmid":"31501481","id":"PMC_31501481","title":"TRAF3 regulates the oncogenic proteins Pim2 and c-Myc to restrain survival in normal and malignant B cells.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31501481","citation_count":17,"is_preprint":false},{"pmid":"23760264","id":"PMC_23760264","title":"The PIM-2 kinase is an essential component of the ultraviolet damage response that acts upstream to E2F-1 and ATM.","date":"2013","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23760264","citation_count":15,"is_preprint":false},{"pmid":"29124675","id":"PMC_29124675","title":"Pim-2 Cooperates with Downstream Factor XIAP to Inhibit Apoptosis and Intensify Malignant Grade in Prostate Cancer.","date":"2017","source":"Pathology oncology research : POR","url":"https://pubmed.ncbi.nlm.nih.gov/29124675","citation_count":14,"is_preprint":false},{"pmid":"31068472","id":"PMC_31068472","title":"Prosurvival kinase PIM2 is a therapeutic target for eradication of chronic myeloid leukemia stem cells.","date":"2019","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/31068472","citation_count":12,"is_preprint":false},{"pmid":"34503251","id":"PMC_34503251","title":"Myeloma-Bone Interaction: A Vicious Cycle via TAK1-PIM2 Signaling.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/34503251","citation_count":11,"is_preprint":false},{"pmid":"20215640","id":"PMC_20215640","title":"Pim2 cooperates with PML-RARalpha to induce acute myeloid leukemia in a bone marrow transplantation model.","date":"2010","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/20215640","citation_count":11,"is_preprint":false},{"pmid":"27397540","id":"PMC_27397540","title":"Characterization of HJ-PI01 as a novel Pim-2 inhibitor that induces apoptosis and autophagic cell death in triple-negative human breast cancer.","date":"2016","source":"Acta pharmacologica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/27397540","citation_count":11,"is_preprint":false},{"pmid":"28944837","id":"PMC_28944837","title":"Role of PIM2 in allergic asthma.","date":"2017","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/28944837","citation_count":10,"is_preprint":false},{"pmid":"33333710","id":"PMC_33333710","title":"PIM2 deletion alleviates lipopolysaccharide (LPS)-induced respiratory distress syndrome (ARDS) by suppressing NLRP3 inflammasome.","date":"2020","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/33333710","citation_count":9,"is_preprint":false},{"pmid":"27770661","id":"PMC_27770661","title":"Pim-2 protects H9c2 cardiomyocytes from hypoxia/reoxygenation-induced apoptosis via downregulation of Bim expression.","date":"2016","source":"Environmental toxicology and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/27770661","citation_count":9,"is_preprint":false},{"pmid":"30607318","id":"PMC_30607318","title":"Computer aided drug design based on 3D-QSAR and molecular docking studies of 5-(1H-indol-5-yl)-1,3,4-thiadiazol-2-amine derivatives as PIM2 inhibitors: a proposal to chemists.","date":"2018","source":"In silico pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30607318","citation_count":9,"is_preprint":false},{"pmid":"26365288","id":"PMC_26365288","title":"Effects of low doses of Tat-PIM2 protein against hippocampal neuronal cell survival.","date":"2015","source":"Journal of the neurological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/26365288","citation_count":8,"is_preprint":false},{"pmid":"23085945","id":"PMC_23085945","title":"Inhibition of Pim2-prolonged skin allograft survival through the apoptosis regulation pathway.","date":"2012","source":"Cellular & molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23085945","citation_count":8,"is_preprint":false},{"pmid":"20592892","id":"PMC_20592892","title":"Ectopic over-expression of oncogene Pim-2 induce malignant transformation of nontumorous human liver cell line L02.","date":"2010","source":"Journal of Korean medical science","url":"https://pubmed.ncbi.nlm.nih.gov/20592892","citation_count":8,"is_preprint":false},{"pmid":"34547720","id":"PMC_34547720","title":"Pim-2 kinase inhibits inflammation by suppressing the mTORC1 pathway in atherosclerosis.","date":"2021","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/34547720","citation_count":7,"is_preprint":false},{"pmid":"15715935","id":"PMC_15715935","title":"Antisense oligodeoxynucleotides targeting the serine/threonine kinase Pim-2 inhibited proliferation of DU-145 cells.","date":"2005","source":"Acta pharmacologica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/15715935","citation_count":7,"is_preprint":false},{"pmid":"38969771","id":"PMC_38969771","title":"Phosphorylation of USP27X by PIM2 promotes glycolysis and breast cancer progression via deubiquitylation of MYC.","date":"2024","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/38969771","citation_count":6,"is_preprint":false},{"pmid":"34770845","id":"PMC_34770845","title":"Engineered Fully Human Single-Chain Monoclonal Antibodies to PIM2 Kinase.","date":"2021","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/34770845","citation_count":6,"is_preprint":false},{"pmid":"28064305","id":"PMC_28064305","title":"Upregulation of PIM2 by Underexpression of MicroRNA-135-5p Improves Survival Rates of Skin Allografts by Suppressing Apoptosis of Fibroblast Cells.","date":"2017","source":"Medical science monitor : international medical journal of experimental and clinical research","url":"https://pubmed.ncbi.nlm.nih.gov/28064305","citation_count":6,"is_preprint":false},{"pmid":"30525315","id":"PMC_30525315","title":"Expression of the PIM2 gene is associated with more aggressive clinical course in patients with chronic lymphocytic leukemia.","date":"2019","source":"Advances in clinical and experimental medicine : official organ Wroclaw Medical University","url":"https://pubmed.ncbi.nlm.nih.gov/30525315","citation_count":5,"is_preprint":false},{"pmid":"22843119","id":"PMC_22843119","title":"MYC and PIM2 co-expression in mouse bone marrow cells readily establishes permanent myeloid cell lines that can induce lethal myeloid sarcoma in vivo.","date":"2012","source":"Molecules and cells","url":"https://pubmed.ncbi.nlm.nih.gov/22843119","citation_count":5,"is_preprint":false},{"pmid":"34111425","id":"PMC_34111425","title":"Inhibition of Pim-2 kinase by LT-171-861 promotes DNA damage and exhibits enhanced lethal effects with PARP inhibitor in multiple myeloma.","date":"2021","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/34111425","citation_count":5,"is_preprint":false},{"pmid":"36612063","id":"PMC_36612063","title":"Pim-2 Kinase Regulates Energy Metabolism in Multiple Myeloma.","date":"2022","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/36612063","citation_count":5,"is_preprint":false},{"pmid":"39747141","id":"PMC_39747141","title":"PIM2 inhibition promotes MCL1 dependency in plasma cells involving integrated stress response-driven NOXA expression.","date":"2025","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/39747141","citation_count":4,"is_preprint":false},{"pmid":"37207916","id":"PMC_37207916","title":"Final step of B-cell differentiation into plasmablasts; the right time to activate plasma cell PIM2 kinase.","date":"2023","source":"Immunology letters","url":"https://pubmed.ncbi.nlm.nih.gov/37207916","citation_count":4,"is_preprint":false},{"pmid":"35920189","id":"PMC_35920189","title":"Targeting PIM2 by JP11646 results in significant antitumor effects in solid tumors.","date":"2022","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/35920189","citation_count":4,"is_preprint":false},{"pmid":"31186757","id":"PMC_31186757","title":"High expression of PIM2 induces HSC proliferation in myelodysplastic syndromes via the IDH1/HIF1-α signaling pathway.","date":"2019","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/31186757","citation_count":4,"is_preprint":false},{"pmid":"38245883","id":"PMC_38245883","title":"Acute accumulation of PIM2 and NRF2 and recovery of β5 subunit activity mitigate multiple myeloma cell susceptibility to proteasome inhibitors.","date":"2024","source":"International journal of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/38245883","citation_count":4,"is_preprint":false},{"pmid":"36659438","id":"PMC_36659438","title":"PIM2 regulates stemness through phosphorylation of 4E-BP1.","date":"2017","source":"Science bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/36659438","citation_count":4,"is_preprint":false},{"pmid":"30096294","id":"PMC_30096294","title":"PIM2 survival kinase is upregulated in a p53-dependent manner in cells treated with camptothecin or co-treated with actinomycin D and nutlin-3a.","date":"2018","source":"Archives of biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/30096294","citation_count":4,"is_preprint":false},{"pmid":"18163587","id":"PMC_18163587","title":"Pim2 inhibitors from the Papua New Guinean plant Cupaniopsis macropetala.","date":"2007","source":"Journal of natural products","url":"https://pubmed.ncbi.nlm.nih.gov/18163587","citation_count":4,"is_preprint":false},{"pmid":"40865347","id":"PMC_40865347","title":"Colchicine alleviates atherosclerosis combined with diabetes mellitus by targeting PIM2 and regulating the NF-κB signaling pathway.","date":"2025","source":"Phytomedicine : international journal of phytotherapy and phytopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/40865347","citation_count":3,"is_preprint":false},{"pmid":"38700370","id":"PMC_38700370","title":"Regnase-1 D141N mutation induces CD4+ T cell-mediated lung granuloma formation via upregulation of Pim2.","date":"2024","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/38700370","citation_count":3,"is_preprint":false},{"pmid":"35696529","id":"PMC_35696529","title":"Pim-2 regulates bone resorptive activity of osteoclasts via V-ATPase a3 isoform expression in periodontal disease.","date":"2022","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/35696529","citation_count":3,"is_preprint":false},{"pmid":"37223703","id":"PMC_37223703","title":"Protective effects of cell permeable Tat-PIM2 protein on oxidative stress induced dopaminergic neuronal cell death.","date":"2023","source":"Heliyon","url":"https://pubmed.ncbi.nlm.nih.gov/37223703","citation_count":2,"is_preprint":false},{"pmid":"40557764","id":"PMC_40557764","title":"Combining PIM-2 and PARP1 Inhibitors Induces MICA Expression on Multiple Myeloma Cells to Activate NK Cells through NKG2D Binding.","date":"2025","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/40557764","citation_count":1,"is_preprint":false},{"pmid":"38263717","id":"PMC_38263717","title":"Identification and assessment of new PIM2 inhibitors for treating hematologic cancers: A combined approach of energy-based virtual screening and machine learning evaluation.","date":"2024","source":"Archiv der Pharmazie","url":"https://pubmed.ncbi.nlm.nih.gov/38263717","citation_count":1,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":49750,"output_tokens":10902,"usd":0.15639,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":21576,"output_tokens":4268,"usd":0.10729,"stage2_stop_reason":"end_turn"},"total_usd":0.26368,"stage1_batch_id":"msgbatch_01CNoDbkChHEkgrJnL7BwtGJ","stage2_batch_id":"msgbatch_016Y4x9E9Wg5VQDANj9quSQD","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2003,\n      \"finding\": \"Pim-2 phosphorylates the BH3 pro-apoptotic protein BAD and maintains rapamycin-resistant phosphorylation of the translational repressor 4E-BP1, thereby promoting cell survival independently of the PI3K/Akt/TOR pathway. Pim-2 also maintained cell size and mitochondrial potential.\",\n      \"method\": \"Constitutive expression in hematopoietic cells, Western blot for phospho-substrates, rapamycin resistance assay, growth factor withdrawal survival assay\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (substrate phosphorylation, pathway independence from PI3K/Akt/TOR, survival assays), replicated across several apoptotic stimuli in same study and confirmed by independent labs\",\n      \"pmids\": [\"12869584\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"PIM-2 directly phosphorylates BAD on serine 112, and this phosphorylation accounts in part for its ability to reverse BAD-induced cell death. Three PIM-2 protein isoforms are produced in cytokine-treated cells; all three are active kinases, and the short (34 kDa) form is the most active at enhancing survival.\",\n      \"method\": \"In vitro kinase assay, overexpression in FDCP1 cells, Western blot, caspase activation assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct in vitro kinase assay identifying substrate and phosphorylation site, replicated functionally in cell-based survival assays, consistent with independent reports on BAD phosphorylation\",\n      \"pmids\": [\"12954615\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Pim-2 is 53% identical to Pim-1 at the amino acid level, shares substrate preference and usage of non-AUG initiation codons with Pim-1, and is X-linked. Proviral activation of Pim-2 compensates for loss of Pim-1 in Eµ-myc/Pim-1−/− mice, indicating functional redundancy and placement in the same oncogenic pathway.\",\n      \"method\": \"PCR-based gene identification, proviral tagging in compound mutant mice (complementation tagging genetic epistasis), sequence analysis\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis in vivo (complementation tagging), replicated by multiple independent proviral insertions; foundational identification paper\",\n      \"pmids\": [\"7781606\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Pim-2-mediated cell survival is dependent on NF-κB activation. Pim-2 phosphorylates and activates the kinase Cot, leading to augmented IκB kinase activity and a shift in nuclear NF-κB from p50 homodimers to p50/p65 heterodimers. Blockade of NF-κB eliminates Pim-2-mediated survival, and Pim-2-driven oncogenesis in vivo requires sustained NF-κB activity.\",\n      \"method\": \"Reporter assays for NF-κB activity, co-immunoprecipitation, NF-κB blockade, in vivo lymphoma model, primary cell experiments\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (reporter assay, Co-IP, primary cell rescue, in vivo model), clear epistasis placing Pim-2 upstream of Cot/IKK/NF-κB\",\n      \"pmids\": [\"15548703\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Pim2 directly phosphorylates TSC2 on Ser-1798, relieving TSC2 suppression of mTOR-C1 and thereby promoting MM cell proliferation. TSC2 is identified as a novel Pim2 substrate.\",\n      \"method\": \"shRNA knockdown, selective small-molecule inhibitor, in vitro kinase assay, co-immunoprecipitation, phospho-specific Western blot\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct in vitro phosphorylation of TSC2, genetic and pharmacological inhibition with consistent phenotype, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"23818547\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Crystal structure of PIM2 kinase in complex with an organoruthenium inhibitor was determined, revealing key differences in the ATP-binding site compared with PIM1 that can be exploited for isoform-selective inhibitor design.\",\n      \"method\": \"X-ray crystallography\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structure with functional inhibitor bound, single study but high-quality structural method\",\n      \"pmids\": [\"19841674\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"PIM2 directly binds to hexokinase-2 (HK2) and phosphorylates HK2 on Thr473, increasing HK2 enzyme activity and glycolysis and stabilizing HK2 protein through the chaperone-mediated autophagy (CMA) pathway. This promotes breast cancer cell growth and paclitaxel resistance.\",\n      \"method\": \"Co-immunoprecipitation, in vitro kinase assay, site-directed mutagenesis, glycolysis assay, xenograft mouse model\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct in vitro kinase assay with mutagenesis, biochemical pathway analyses (CMA), in vivo validation; single lab with multiple orthogonal methods\",\n      \"pmids\": [\"29985480\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Pim-2 kinase phosphorylates the N-terminal domain of Foxp3 at multiple sites, leading to decreased suppressive function of regulatory T cells (Tregs), altered expression of Treg-related proteins, and increased Treg lineage stability. Pharmacological or genetic inhibition of Pim-2 enhances Treg suppressive function.\",\n      \"method\": \"In vitro kinase assay, genetic knockout in murine Treg cells, pharmacological inhibition, DSS-induced colitis model\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct in vitro phosphorylation of Foxp3, genetic knockout with defined immunological phenotype, in vivo disease model; single lab with multiple orthogonal methods\",\n      \"pmids\": [\"25987564\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"PIM2 directly phosphorylates HSF1 at Thr120, disrupting HSF1 binding to the E3 ubiquitin ligase FBXW7 and stabilizing HSF1 protein. Thr120 phosphorylation promotes HSF1 binding to the PD-L1 promoter and enhances PD-L1 expression, driving breast cancer tumorigenesis.\",\n      \"method\": \"In vitro kinase assay, co-immunoprecipitation, site-directed mutagenesis, chromatin immunoprecipitation, xenograft model\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct in vitro phosphorylation with mutagenesis, ChIP linking phosphorylated substrate to downstream transcription, in vivo validation; single lab with multiple orthogonal methods\",\n      \"pmids\": [\"31409638\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"PIM2 binds to and directly phosphorylates pyruvate kinase M2 (PKM2) on Thr-454, increasing PKM2 protein levels and promoting glycolysis (the Warburg effect). The phosphorylation-defective PKM2 mutant shows reduced glycolysis, co-activation of HIF-1α and β-catenin, and increased mitochondrial respiration.\",\n      \"method\": \"Multiple biochemical pulldown/co-IP approaches in vitro and in cells, in vitro kinase assay, phosphorylation-defective mutant analysis, glycolysis assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct in vitro phosphorylation with mutant validation, multiple biochemical interaction methods, glycolytic functional readouts; single lab\",\n      \"pmids\": [\"24142698\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"RAG-induced DNA double-strand breaks activate ATM, which induces Pim2 kinase expression in pre-B cells. Pim2 then phosphorylates BAD to promote survival, but unlike IL-7-induced Pim1, Pim2 has antiproliferative functions that prevent pre-B cells with RAG DSBs from entering S phase.\",\n      \"method\": \"Genetic mouse model (ATM deficiency, Pim2 knockout), BAD phosphorylation Western blot, cell cycle analysis, survival assays\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis with ATM KO and Pim2 KO, clear context-dependent functional distinction from Pim1, multiple readouts; single lab\",\n      \"pmids\": [\"22201128\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"PIM2 binds to AMPKα1 and directly phosphorylates it on Thr467, leading to decreased AMPKα1 kinase activity, which in turn promotes aerobic glycolysis and tumor growth in endometrial cancer.\",\n      \"method\": \"Co-immunoprecipitation, in vitro kinase assay, site-directed mutagenesis, glycolysis assay, xenograft and PIM2 KO mouse models\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct in vitro kinase assay with defined phosphorylation site, KO mouse validation, functional glycolysis and tumor growth readouts; single lab with multiple orthogonal methods\",\n      \"pmids\": [\"31358902\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Pim-2 phosphorylates the cell cycle inhibitor p21(Cip1/WAF1) on Thr145 in vitro and in vivo, enhancing p21 protein stability and resulting in G1/S cell cycle arrest and inhibition of cell proliferation in HCT116 cells. Pim-2 does not influence nuclear localization of p21 in these cells.\",\n      \"method\": \"In vitro kinase assay, overexpression and siRNA knockdown, Western blot for p21 stability, cell cycle analysis\",\n      \"journal\": \"The international journal of biochemistry & cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct in vitro kinase assay, in vivo phosphorylation confirmed, genetic manipulation with defined cell cycle phenotype; single lab\",\n      \"pmids\": [\"20307683\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"The forkhead transcription factor CHES1/FOXN3 directly binds the PIM2 promoter and represses PIM2 expression. Reduced PIM2 leads to decreased phosphorylation of 4E-BP1, and overexpression of PIM2 or eIF4E partially reverses the antiproliferative effect of CHES1, placing PIM2 downstream of CHES1 in a protein biosynthesis control pathway.\",\n      \"method\": \"Chromatin immunoprecipitation, shRNA knockdown, rescue overexpression, 4E-BP1 phosphorylation Western blot\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP for direct promoter binding, epistasis via rescue experiment, multiple cell lines; single lab\",\n      \"pmids\": [\"24403608\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"PIM2 promotes persistent STAT3 activation through induction of cytokines, and activated STAT3 in turn increases PIM2 expression, forming a positive feedback loop. This loop drives EMT in breast cancer via ZEB1, and targeting either PIM2, STAT3, or PIM2-dependent cytokines suppresses migratory and invasive properties.\",\n      \"method\": \"Genetic knockdown/overexpression, cytokine neutralization, migration/invasion assays, Western blot\",\n      \"journal\": \"Cancer science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — functional genetic experiments with signaling readouts, but mechanistic depth is limited (no direct substrate assay); single lab\",\n      \"pmids\": [\"25854938\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Pim-2 co-expresses with eIF4B in prostate cancer cells and determines the phosphorylation level of eIF4B; higher Pim-2 expression correlates with more eIF4B phosphorylation and lower apoptosis. siRNA knockdown of Pim-2 reduces p-eIF4B and increases apoptosis.\",\n      \"method\": \"siRNA knockdown, transfection overexpression, Western blot for p-eIF4B, apoptosis assay, immunofluorescence co-localization\",\n      \"journal\": \"The Prostate\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — correlation-based phosphorylation evidence without direct in vitro kinase assay for eIF4B; multiple cell line experiments; single lab\",\n      \"pmids\": [\"23813671\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Pim-2 activates API-5 phosphorylation via the NF-κB pathway to inhibit apoptosis of liver cells; NF-κB inhibition by parthenolide reverses Pim-2-induced API-5 phosphorylation and increases apoptosis.\",\n      \"method\": \"Transfection and siRNA, NF-κB activity assay, Western blot for phospho-API-5, apoptosis analysis with NF-κB inhibitor parthenolide\",\n      \"journal\": \"Pathology oncology research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — genetic manipulation plus pharmacological inhibition with defined signaling readouts; no direct in vitro kinase assay; single lab\",\n      \"pmids\": [\"19821157\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Pim-2 kinase controls autophagy in chondrocytes: it promotes expression and organization of autophagic proteins LC3 and Beclin-1, enhances lysosomal acidification, and modulates BAD activity. PIM-2-silenced chondrocytes show disrupted autophagic response. These effects are independent of Akt-1.\",\n      \"method\": \"siRNA silencing, immunofluorescence for LC3/Beclin-1, lysosomal acidification assay, rapamycin sensitization, Akt-1 independence controls\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA with defined organelle/autophagic phenotype and independence from Akt-1 established by parallel controls; single lab\",\n      \"pmids\": [\"17476689\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"PIM2 activity is required for phosphorylation of 4E-BP1 and BAD in liver cancer cells, and its kinase activity on these downstream mediators correlates with pro-survival functions.\",\n      \"method\": \"Pim-2 overexpression and knockdown in liver cancer cells, Western blot for phospho-4E-BP1 and phospho-BAD, IL-3 deprivation survival assay\",\n      \"journal\": \"The Journal of surgical research\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — indirect evidence from overexpression/knockdown correlating with phospho-substrates; no direct in vitro kinase assay; single lab; confirming known substrates in a new context\",\n      \"pmids\": [\"18675992\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"The 34 kDa isoform of PIM-2 (but not the 41 kDa isoform) can, when N-terminally HA-tagged, induce G1 cell cycle arrest and apoptosis in HeLa cells in a kinase-dependent and p73-dependent manner, associated with increased T14/Y15 phosphorylation of CDK2, proteasome-dependent downregulation of CDC25A, and upregulation of p57, E2F-1, and p73.\",\n      \"method\": \"Transient overexpression with isoform-specific and kinase-dead constructs, flow cytometry, dominant-negative p73, p73 siRNA, Western blot\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — kinase-dead and dominant-negative controls, p73 genetic epistasis; single lab, single cell line; context-specific (HA-tagged 34 kDa form only)\",\n      \"pmids\": [\"22506047\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"PIM-2 expression and activity increase upon UVC radiation in U2OS cells. PIM-2 accelerates removal of UV-induced DNA lesions, reduces γH2AX accumulation, and protects cells through increased E2F-1 and activated ATM levels. Epistasis places PIM-2 upstream of E2F-1 and ATM in the UV-damage response.\",\n      \"method\": \"PIM-2 silencing, overexpression, UV survival assay, γH2AX assay, E2F-1 siRNA, ATM kinase inhibition, DNA lesion removal assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis with E2F-1 and ATM, defined molecular phenotypes, multiple perturbations; single lab\",\n      \"pmids\": [\"23760264\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Pim-2 is identified as a novel RSK2-interacting upstream regulator in FLT3-ITD AML; ectopic RSK2 expression rescues viability of Pim2-depleted cells. Pim2 predominantly controls apoptosis through Bax expression and mitochondrial disruption in FLT3-ITD AML cells.\",\n      \"method\": \"Proteomics/transcriptomics in Pim2-depleted cells, ectopic RSK2 rescue, viability assays, Bax/mitochondria disruption analysis, in vivo mouse model\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic rescue epistasis, proteomic identification of target, in vivo validation; single lab\",\n      \"pmids\": [\"28914261\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Pim2 negatively regulates DNA damage response in multiple myeloma: Pim2 knockdown upregulates DDR markers mimicking doxorubicin treatment, placing Pim2 as a negative regulator of the DDR pathway downstream of doxorubicin-DNA binding. Doxorubicin treatment decreases Pim2 levels.\",\n      \"method\": \"shRNA knockdown of Pim2, doxorubicin treatment, Western blot for DDR markers, overexpression survival assay\",\n      \"journal\": \"Blood cancer journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — genetic knockdown with defined molecular DDR phenotype; single lab, limited mechanistic depth on direct substrate\",\n      \"pmids\": [\"27564460\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"All three Pim2 isoforms localize to the cytoplasm in leukemic cells and are degraded by the proteasome without detectable ubiquitination—purified 20S proteasome particles degrade Pim2 in vitro. Pim2 mRNA accumulation is controlled by erythropoietin via STAT5; translation is not regulated by mTORC1.\",\n      \"method\": \"Subcellular fractionation, proteasome inhibitors (half-life analysis), E1 inhibitor Pyr41, in vitro 20S proteasome degradation assay, STAT5 inhibition, signaling pathway inhibitors\",\n      \"journal\": \"Bioscience reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution of ubiquitin-independent 20S proteasomal degradation, direct localization by fractionation, multiple pharmacological controls; single lab with multiple orthogonal methods\",\n      \"pmids\": [\"26500282\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"PIM2 directly binds tristetraprolin (TTP) and promotes its proteasomal degradation independently of PIM2 kinase activity, thereby de-repressing TTP-mediated inhibition of breast cancer cell proliferation and migration.\",\n      \"method\": \"Co-immunoprecipitation, kinase-dead PIM2 mutant, ubiquitin-proteasome pathway assays, immunohistochemistry correlation, in vivo xenograft\",\n      \"journal\": \"Molecular oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — kinase-dead mutant distinguishes kinase-independent mechanism, Co-IP, proteasome assay, in vivo validation; single lab\",\n      \"pmids\": [\"29570932\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"PIM2 inhibition reduces phosphorylation of 4E-BP1 (Thr37/46 and Ser65), establishing p4E-BP1 as a molecular biomarker of PIM2 kinase activity and indicating PIM2 involvement in regulating mTORC1.\",\n      \"method\": \"Pharmacological inhibition and genetic knockdown of PIM2, Western blot for phospho-4E-BP1, lymphoma cell lines\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — genetic plus pharmacological inhibition with consistent phospho-substrate readout; indirect evidence for mTORC1 regulation; multiple cell systems\",\n      \"pmids\": [\"21937691\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"In CML stem cells (CMLSCs), PIM2 expression is maintained by both a BCR-ABL-dependent STAT5-mediated pathway and a BCR-ABL-independent STAT4-mediated pathway. PIM2 phosphorylates and inhibits BAD, contributing to imatinib resistance in CMLSCs.\",\n      \"method\": \"Single-cell RNA-seq, BCR-ABL identification, STAT4/STAT5 pathway analysis, BAD phosphorylation Western blot, mouse CML model, PIM inhibitor combined treatment\",\n      \"journal\": \"PNAS\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — single-cell genomics with pathway validation, in vivo mouse CML model, mechanistic assignment to two STAT pathways; single lab\",\n      \"pmids\": [\"31068472\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Pim-2 regulates osteoblastogenesis negatively; enforced expression abrogates BMP-2-induced osteoblastogenesis while Pim-2 inhibition or siRNA restores osteoblastogenesis. The inhibitor SMI-16a potentiates BMP-2 anabolic signaling while suppressing TGF-β signaling.\",\n      \"method\": \"siRNA knockdown, overexpression, SMI-16a inhibitor treatment, BMP-2-induced osteoblastogenesis assay, TGF-β/BMP signaling Western blot, in vivo MM animal model\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain and loss of function with defined signaling pathway readouts, in vivo validation; single lab\",\n      \"pmids\": [\"24787487\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"PIM2 kinase sustains G1/S transition during plasmablast generation by acting on CDC25A and p27Kip1, and hinders caspase 3-driven apoptosis through BAD phosphorylation and cytoplasmic stabilization of p21Cip1.\",\n      \"method\": \"Morpholino antisense inhibition, pharmacological PIM inhibition, Western blot for CDC25A/p27Kip1/BAD phosphorylation/p21Cip1, flow cytometry for cell cycle and apoptosis\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — novel morpholino antisense strategy plus pharmacological inhibition with multiple defined molecular targets; consistent with known PIM2 substrate biology; single lab\",\n      \"pmids\": [\"35108359\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"PIM2 directly phosphorylates PFKFB3 at Ser478, enhancing PFKFB3 protein stability through the ubiquitin-proteasome pathway, which promotes glycolysis, BC cell growth, and paclitaxel resistance.\",\n      \"method\": \"Mass spectrometry, co-immunoprecipitation, in vitro kinase assay, PFKFB3 site-specific mutants, ubiquitination assay, xenograft model\",\n      \"journal\": \"Clinical and translational medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct in vitro kinase assay with site-specific mutant, ubiquitination pathway assay, in vivo validation; single lab with multiple orthogonal methods\",\n      \"pmids\": [\"33931981\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"PIM2 directly phosphorylates PFKFB4 on Thr140 and enhances PFKFB4 protein expression through the ubiquitin-proteasome pathway, promoting glycolysis and cell growth in endometriosis.\",\n      \"method\": \"Co-immunoprecipitation, in vitro kinase assay, site-directed mutagenesis, ubiquitin-proteasome assay, in vivo endometriosis model\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct in vitro kinase assay with mutagenesis, ubiquitination pathway validation, in vivo model; single lab\",\n      \"pmids\": [\"36109523\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"PIM-2 isoform negatively regulates T cell responses to alloantigen (unlike PIM-1 and PIM-3, which are positive regulators); PIM-2-deficient T cells show increased Th1 differentiation, proliferation, and migration, leading to accelerated GVHD; PIM-2 also suppresses CD8+ T cell antitumor responses.\",\n      \"method\": \"Pim-2 genetic knockout mice, allogeneic bone marrow transplantation model, syngeneic tumor rejection model, adoptive T cell transfer, flow cytometry, rescue expression experiments\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO with rescue expression, multiple in vivo models (GVHD, tumor rejection, adoptive transfer), isoform-specific functional distinction from PIM-1/3; single lab with multiple orthogonal approaches\",\n      \"pmids\": [\"29781812\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"TRAF3 deficiency induces Pim2 upregulation in B cells via STAT3 (independent of NF-κB2), and elevated Pim2 in turn increases c-Myc protein levels with reduced c-Myc ubiquitination.\",\n      \"method\": \"TRAF3 knockout B cells, STAT3 inhibition, Pim inhibitor treatment, c-Myc ubiquitination assay, Western blot\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — TRAF3 KO and STAT3 inhibition epistasis, ubiquitination assay; single lab\",\n      \"pmids\": [\"31501481\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"PIM2 kinase phosphorylates the serine/threonine kinase Bim on Ser65, promotes its proteasomal degradation, and protects H9c2 cardiomyocytes from hypoxia/reoxygenation-induced apoptosis. A Bim S65A mutation reverses the anti-apoptotic role of Pim-2.\",\n      \"method\": \"Co-immunoprecipitation (Pim-2/Bim interaction), site-directed mutagenesis (Bim S65A), proteasome inhibitor MG132, overexpression and siRNA, Western blot for Cyt C\",\n      \"journal\": \"Environmental toxicology and pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP for interaction, mutagenesis for phosphorylation site, proteasome assay; single lab, single cell line\",\n      \"pmids\": [\"27770661\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"PIM2 directly phosphorylates PGK1 at Ser203, PDHA1 at Ser300, and PFKFB2 at Ser466, promoting glycolytic reprogramming during M1 macrophage polarization and inflammatory arthritis.\",\n      \"method\": \"Conditional macrophage-specific Pim2 knockout, in vitro kinase assays (implied by direct phosphorylation claim and biochemical analyses), glycolytic assays, CIA arthritis model\",\n      \"journal\": \"Cellular & molecular immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo conditional KO with defined metabolic phenotype, direct phosphorylation sites identified; single lab, abstract does not explicitly state reconstituted in vitro assay\",\n      \"pmids\": [\"40000906\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"PIM2 activates NF-κB signaling in hepatocellular carcinoma by upregulating phosphorylation of RIPK2. TNFα induces PIM2 expression, and PIM2 in turn upregulates TNFα, forming a positive feedback loop.\",\n      \"method\": \"Functional studies with overexpression/knockdown, Western blot for phospho-RIPK2, NF-κB reporter, TNFα stimulation experiments, in vivo xenograft\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — phosphorylation of RIPK2 by PIM2 is inferred from expression manipulation without direct in vitro kinase assay; single lab\",\n      \"pmids\": [\"32641749\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"PIM2 directly interacts with NLRP3 and promotes LPS-triggered NLRP3 inflammasome activation (Caspase-1, IL-1β) in macrophages; Pim2 knockout significantly alleviated ARDS in LPS-challenged mice.\",\n      \"method\": \"Co-immunoprecipitation, PIM2 overexpression and knockdown, Pim2 knockout mice, ARDS mouse model, inflammasome component Western blot\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP for direct interaction, genetic KO in vivo; no in vitro kinase assay for direct phosphorylation of NLRP3; single lab\",\n      \"pmids\": [\"33333710\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"PIM2 phosphorylates FBP1 on Ser144, abrogating FBP1 interaction with NF-κB p65 and promoting p65 stability through the CHIP-mediated proteasome pathway, leading to increased PD-L1 expression and breast tumor growth.\",\n      \"method\": \"Immunoaffinity purification, co-immunoprecipitation, in vitro kinase assay, ubiquitination/proteasome assay, PIM2 KO mice, in vivo xenograft\",\n      \"journal\": \"Theranostics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct in vitro kinase assay, Co-IP, ubiquitination assay, KO mouse model; single lab with multiple orthogonal methods\",\n      \"pmids\": [\"32754266\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"A regulatory feedback loop exists between HIF-1α and PIM2: HIF-1α induces PIM2 expression by binding hypoxia-responsive elements (HREs) in the PIM2 promoter, and PIM2 in turn interacts with HIF-1α (at its transactivation domain) as a co-factor (not a kinase) to enhance HIF-1α transcriptional activity.\",\n      \"method\": \"ChIP for HRE binding, co-immunoprecipitation of PIM2/HIF-1α, domain-mapping, glucose metabolism assay, hypoxia experiments\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and Co-IP with domain mapping; single lab; notable finding that PIM2 acts as co-factor not kinase for HIF-1α\",\n      \"pmids\": [\"24505470\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"PIM2 inhibition reduces phosphorylated BAD production and activates ISR-mediated NOXA expression, shifting plasma cells to MCL1 dependence. Combined PIM/MCL1 inhibition synergistically controls tumor growth, and ISR-specific inhibition reverses this synergy.\",\n      \"method\": \"PIM2 inhibition, MCL1 inhibitor, ISR inhibitor (genetic and pharmacological), Western blot for phospho-BAD and NOXA, xenograft mouse model\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological and genetic inhibition with defined downstream signaling (ISR/NOXA), in vivo xenograft, multiple perturbations; single lab\",\n      \"pmids\": [\"39747141\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"PIM2 regulates stemness in embryonic stem cells by directly phosphorylating 4E-BP1, leading to eIF4E release and facilitated translation of pluripotent genes. Pim2 knockout inhibits ESC self-renewal and differentiation capability.\",\n      \"method\": \"Pim2 knockout, in vitro kinase assay for 4E-BP1 phosphorylation, eIF4E cap-binding assay, self-renewal and differentiation assays\",\n      \"journal\": \"Science bulletin\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — in vitro kinase assay and KO phenotype in ESCs; single lab, single study\",\n      \"pmids\": [\"36659438\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"PIM2 phosphorylates USP27X, promoting USP27X deubiquitylase activity toward MYC, thereby stabilizing MYC protein and increasing HK2-mediated aerobic glycolysis in breast cancer. This PIM2-USP27X-MYC axis is validated in PIM2-knockout mice.\",\n      \"method\": \"Co-immunoprecipitation, in vitro kinase assay, deubiquitylation assay, MYC stability Western blot, glycolysis assay, PIM2 KO mouse model\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct kinase assay, functional deubiquitylation assay, KO mouse validation; single lab with multiple orthogonal methods\",\n      \"pmids\": [\"38969771\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Pim-2 regulates osteoclastic bone resorption activity by controlling expression of the V-ATPase a3 isoform; Pim-2 siRNA silencing diminishes RANKL-induced resorptive activity and attenuates RANKL-triggered a3 stimulation without affecting osteoclast differentiation. Pim-2 overexpression stimulates a3 subunit expression and induces bone resorption.\",\n      \"method\": \"siRNA silencing and retroviral overexpression in BMMs, RANKL-induced osteoclastogenesis, dentin bone resorption assay, RT-PCR/Western blot for a3 isoform\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain and loss of function with defined molecular target (a3 isoform) and functional bone resorption readout; single lab\",\n      \"pmids\": [\"35696529\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"p53 activation (via actinomycin D + nutlin-3a) leads to accumulation of PIM2 in a p53-dependent manner (abrogated by p53 knockdown), which then phosphorylates BAD on Ser136, providing an inactivating (pro-survival) signal concurrent with p53-induced apoptosis.\",\n      \"method\": \"Antibody arrays for apoptotic proteins, Western blot for phospho-BAD, p53 knockdown, A549 cells\",\n      \"journal\": \"Archives of biochemistry and biophysics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — p53 dependency established by KD, phospho-BAD as PIM2 substrate inferred rather than directly assayed; single lab\",\n      \"pmids\": [\"30096294\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"PIM2 is a constitutively active serine/threonine kinase whose activity is primarily regulated at the transcriptional level (downstream of cytokines via JAK/STAT5 and NF-κB, and by p53 and HIF-1α) and post-translationally through ubiquitin-independent 20S proteasomal degradation; it promotes cell survival and proliferation by directly phosphorylating a broad set of substrates—including BAD (Ser112), 4E-BP1, TSC2 (Ser1798), p21(Thr145), Bim (Ser65), HK2 (Thr473), PKM2 (Thr454), AMPKα1 (Thr467), HSF1 (Thr120), FBP1 (Ser144), PFKFB3 (Ser478), PFKFB4 (Thr140), PGK1 (Ser203), PDHA1 (Ser300), PFKFB2 (Ser466), and USP27X—thereby integrating anti-apoptotic signaling (via BAD, Bim, Bcl-2 family), mTORC1 activation (via TSC2), translational control (via 4E-BP1/eIF4E), Warburg-effect glycolysis, NF-κB activation (via Cot/IKK), immune regulation (via Foxp3 in Tregs and T cell responses), DNA damage response, and NLRP3 inflammasome activation into a unified pro-survival and oncogenic program.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"PIM2 is a constitutively active, cytoplasmic serine/threonine kinase that integrates cytokine and stress signaling into a coordinated pro-survival, pro-proliferative, and metabolic program, with broad oncogenic consequences [#0, #2]. Its central survival output is phosphorylation and inactivation of the pro-apoptotic BH3 protein BAD (Ser112) together with rapamycin-resistant phosphorylation of the translational repressor 4E-BP1, sustaining cell survival, cell size, and mitochondrial potential independently of PI3K/Akt/TOR [#0, #1]. PIM2 reinforces apoptotic resistance through additional substrates—phosphorylating Bim (Ser65) to drive its proteasomal degradation [#33] and stabilizing p21 via Thr145 phosphorylation [#12]—and it couples survival to mTORC1 activation by directly phosphorylating TSC2 (Ser1798) to relieve its suppression of mTOR-C1 [#4]. A second major axis is glycolytic (Warburg) reprogramming: PIM2 binds and phosphorylates hexokinase-2 (Thr473), PKM2 (Thr454), and inhibits AMPKα1 (Thr467), and phosphorylates PFKFB3 (Ser478) and PFKFB4 (Thr140) to stabilize them through the ubiquitin-proteasome pathway, collectively enhancing aerobic glycolysis and tumor growth [#6, #9, #11, #29, #30]. PIM2 also activates NF-κB signaling by phosphorylating and activating Cot, which augments IκB kinase activity, an event required for PIM2-mediated survival and oncogenesis [#3]. Beyond canonical kinase activity, PIM2 functions kinase-independently—degrading tristetraprolin to de-repress proliferation [#24] and acting as a transcriptional co-factor for HIF-1α [#38]—and it has context-specific immunoregulatory roles, phosphorylating Foxp3 to weaken Treg suppression [#7] and negatively regulating alloreactive T cell responses [#31]. PIM2 itself is regulated transcriptionally downstream of JAK/STAT5 and STAT3/STAT4, p53, HIF-1α, and CHES1/FOXN3, and post-translationally by ubiquitin-independent degradation by the 20S proteasome [#23, #13, #38, #43, #26].\",\n  \"teleology\": [\n    {\n      \"year\": 1995,\n      \"claim\": \"Established PIM2 as a distinct kinase functionally redundant with PIM1, placing it within the same oncogenic pathway and explaining why it can substitute for PIM1 loss.\",\n      \"evidence\": \"PCR-based gene identification and proviral complementation tagging in Eµ-myc/Pim-1−/− mice\",\n      \"pmids\": [\"7781606\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define direct substrates\", \"Mechanism of constitutive activity not addressed\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Defined PIM2's core survival mechanism: direct phosphorylation of BAD (Ser112) and rapamycin-resistant 4E-BP1 phosphorylation, establishing a PI3K/Akt/TOR-independent survival pathway.\",\n      \"evidence\": \"Constitutive expression in hematopoietic/FDCP1 cells, in vitro kinase assay, growth-factor withdrawal survival assays\",\n      \"pmids\": [\"12869584\", \"12954615\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which 4E-BP1 phosphorylation is maintained not resolved\", \"Relative contribution of three isoforms to physiological survival unclear\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Showed PIM2-driven survival and oncogenesis require NF-κB, placing PIM2 upstream of the Cot/IKK/NF-κB axis.\",\n      \"evidence\": \"Reporter assays, Co-IP, NF-κB blockade, primary cell rescue, in vivo lymphoma model\",\n      \"pmids\": [\"15548703\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct phosphorylation site on Cot not mapped\", \"Whether NF-κB activation is universal across PIM2 contexts unknown\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Provided structural basis for PIM2 inhibition, revealing ATP-pocket differences from PIM1 exploitable for isoform-selective inhibitors.\",\n      \"evidence\": \"X-ray crystallography of PIM2 with an organoruthenium inhibitor\",\n      \"pmids\": [\"19841674\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No substrate-bound structure\", \"Basis of constitutive activity not structurally explained\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Connected PIM2 to mTORC1 and Warburg metabolism via direct phosphorylation of TSC2 (Ser1798) and PKM2 (Thr454), extending its function beyond survival into proliferation and glycolysis.\",\n      \"evidence\": \"In vitro kinase assays, knockdown/inhibitor, phospho-defective mutants, glycolysis assays in MM and other cells\",\n      \"pmids\": [\"23818547\", \"24142698\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Crosstalk between TSC2/mTORC1 and direct 4E-BP1 phosphorylation not disentangled\", \"In vivo metabolic consequences only partially characterized\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Defined PIM2's post-translational regulation and immunoregulatory role: ubiquitin-independent 20S proteasomal degradation, STAT5-controlled mRNA, and Foxp3 phosphorylation weakening Treg suppression.\",\n      \"evidence\": \"In vitro 20S degradation reconstitution, fractionation, STAT5 inhibition; in vitro Foxp3 kinase assay with Treg knockout and colitis model\",\n      \"pmids\": [\"26500282\", \"25987564\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Degron motif targeting PIM2 to 20S proteasome not defined\", \"Foxp3 phosphosites and their individual contributions incompletely mapped\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Revealed a kinase-independent mode of action—PIM2 degrades tristetraprolin to de-repress proliferation—and a metabolic axis stabilizing HK2 via chaperone-mediated autophagy.\",\n      \"evidence\": \"Co-IP, kinase-dead mutants, proteasome/CMA assays, in vitro kinase assay (HK2 Thr473), xenografts\",\n      \"pmids\": [\"29570932\", \"29985480\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How a kinase mediates substrate degradation without phosphorylation is mechanistically unresolved\", \"Determinants choosing kinase-dependent vs -independent outputs unknown\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Extended the glycolytic and immune-evasion network: PIM2 inhibits AMPKα1 (Thr467), and stabilizes HSF1 (Thr120) to drive PD-L1 expression.\",\n      \"evidence\": \"In vitro kinase assays with site mutants, ChIP, KO mouse and xenograft models\",\n      \"pmids\": [\"31358902\", \"31409638\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Integration of multiple metabolic substrates into a single flux model lacking\", \"PD-L1 immune-evasion consequence not tested in immunocompetent tumor settings here\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Linked PIM2 to NF-κB stabilization and innate immunity: phosphorylation of FBP1 (Ser144) stabilizing p65/PD-L1, and direct binding to NLRP3 promoting inflammasome activation.\",\n      \"evidence\": \"In vitro kinase/ubiquitination assays, Co-IP, PIM2 KO mice, ARDS model\",\n      \"pmids\": [\"32754266\", \"33333710\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether NLRP3 is a direct phosphorylation substrate not established\", \"RIPK2 phosphorylation (idx 35) inferred without in vitro kinase assay\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Consolidated PIM2 as a master glycolytic regulator stabilizing PFKFB3 (Ser478) and PFKFB4 (Thr140) via the ubiquitin-proteasome pathway across cancer and endometriosis.\",\n      \"evidence\": \"Mass spectrometry, in vitro kinase assays with site mutants, ubiquitination assays, xenograft/in vivo models\",\n      \"pmids\": [\"33931981\", \"36109523\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Common mechanism by which phosphorylation blocks ubiquitination across these substrates not unified\", \"Tissue specificity of substrate selection unclear\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Identified a PIM2-USP27X-MYC axis in which PIM2 phosphorylation of USP27X stabilizes MYC to boost HK2-driven glycolysis, integrating deubiquitination control into PIM2's metabolic program.\",\n      \"evidence\": \"Co-IP, in vitro kinase assay, deubiquitylation assay, MYC stability and glycolysis assays, PIM2 KO mice\",\n      \"pmids\": [\"38969771\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"USP27X phosphosite not specified in the finding\", \"Relationship to direct HK2 phosphorylation pathway not reconciled\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How PIM2's many parallel substrate axes (survival, mTORC1, glycolysis, NF-κB, immune regulation) are prioritized in a given cell type, and what governs its kinase-dependent versus kinase-independent and co-factor functions, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model of substrate selection across tissues\", \"Determinants of kinase-independent vs catalytic activity undefined\", \"Structural basis of constitutive activity and isoform-specific functions incompletely understood\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 1, 4, 6, 9, 11, 12, 29, 30, 33, 34, 37, 41]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [1, 4, 6, 9, 11, 29, 30, 37]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [38]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [11, 24]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [23]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [0, 1, 33, 39, 43]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [6, 9, 11, 29, 30, 34, 41]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [3, 4, 35]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [7, 31, 36]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [12, 19, 28]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [23, 24, 29, 30, 37]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"BAD\", \"TSC2\", \"HK2\", \"PKM2\", \"PRKAA1\", \"HSF1\", \"HIF1A\", \"NLRP3\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}